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ABSTRACT OF THE DISSERTATION
GUT INTEGRITY, MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION,
INFLAMMATION AND VITAMIN D IN DRUG USERS LIVING WITH HIV
by
Jacqueline Hernandez
Florida International University, 2020
Miami, Florida
Professor Marianna K. Baum, Major Professor
The purpose of this study was to examine associations between MT, immune
activation, inflammation, gut integrity and vitamin D status in the context of cocaine use
among People Living with HIV (PLWH). One hundred cocaine and non-cocaine users
living with HIV were selected from the Miami Adult Studies in HIV cohort. Blood
samples were collected to assess MT (LPS), immune activation (sCD163 and sCD27),
inflammation (IL-6, TNF-a, hs-CRP, IL-17 and IL-22), gut integrity damage (I-FABP)
and vitamin D status. Data on socio-demographic characteristics, anthropometrics, diet
and disease progression were collected. Descriptive statistics, independent t-test, multiple
linear and logistic regressions were conducted to analyze the data.
The non-cocaine group had a greater proportion of participants (66%, n=66), than
cocaine group (34%, n=34). For the two groups, mean age was 53.37±6.88 years old,
most participants were male (51%), and African Americans (66%). All participants were
on ART and had controlled viral load (<200 copies/mL). Half of the participants were
considered vitamin D deficient. Cocaine users had higher levels of MT and I-FABP than
non-users (P<0.001 and P=0.014). Cocaine use was a associated with MT (LPS)
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(P=0.048), immune activation (sCD163, P<0.001 and sCD27, P=0.03) and gut integrity
damage (I-FABP) (P=0.042). Cocaine users had 6.66 times more likely to exhibit high
MT levels than non-users (OR: 6.65 95% CI: 2.42, 18.25; P<0.001). In vitamin D
deficient participants, those who used cocaine had higher MT levels than non-users
(P=0.043). In cocaine users, alcohol use and BMI were associated with inflammation
(P=0.037 and P=0.045). Cocaine users with intestinal inflammation, had 3.42 times
higher odds to exhibit high levels of gut integrity damage than cocaine users without
intestinal inflammation (OR: 3.42 95% CI: 1.07, 10.90; P=0.037). Vitamin D status was
not associated with immune activation, inflammation and gut integrity damage in our
participants.
Our data suggested that cocaine use was associated with MT, immune activation,
inflammation and the damage to the gut integrity in PLWH despite ART use and viral
suppression. Therefore, there is a need to develop effective interventions that target gut
health and counseling on drug abuse, to improve MT and immune activation among
PLWH.
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GUT INTEGRITY, MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION,
INFLAMMATION AND VITAMIN D IN DRUG USERS LIVING WITH HIV
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CHAPTER I: INTRODUCTION
Statement of Problem
The Centers for Disease Control and Prevention ranks Florida as first among 50
states in the number of Human Immunodeficiency Virus (HIV) diagnosis in 2017.1
Miami-Dade County alone accounts for 27,969 presumed living HIV cases as of June
2018, posing it as one of the geographical areas with the highest HIV rates in the nation.2
HIV infection is characterized for destruction of immune system cells, generating
a broad range of physio pathological consequences that affects all organ systems, in
particular the gastrointestinal tract.3
The gastrointestinal (GI) tract mucosa is considered one of the most active and
important tissues of the immune system. The anatomical, histological and physiological
characteristics of the GI mucosa provide a barrier against microorganisms. The
enterocyte is the basic unit of the GI mucosa, serving as the single layer of cells for
absorption of nutrients, water, and protection from external pathogens. Therefore,
preserving the integrity of the GI mucosa is an essential task for the human body and the
immune system.4
The integrity of the GI mucosa is affected by several diseases, including HIV.4
Studies revealed that People Living with HIV (PLWH) develop dramatic changes in the
gut, debilitating structures of the enterocyte and creating a dysbiotic microbiome. These
changes promote the passage of GI microflora or its products from the GI tract into the
systemic circulation, a process called Microbial Translocation (MT); immune activation,
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inflammation and ultimately HIV disease progression.5–17 Cumulative evidence
demonstrated that products of MT, specifically Lipopolysaccharide (LPS) induce a
massive immune activation as assessed by soluble CD14 (sCD14), and inflammation, as
measured by pro-inflammatory cytokines Tumor Necrosis Factor- alpha (TNF-α) and Creactive protein (CRP), which are considered hallmarks in predicting clinical outcomes
and disease progression during HIV infection regardless of Antiretroviral Therapy (ART)
use.18–24
Vitamin D plays an essential role in several physio pathological processes since
Vitamin D Receptor (VDR) is expressed in many areas of human body.25 VDR is highly
expressed in the intestine26 and it regulates transcellular calcium transport, protects
mucosa barrier integrity and controls mucosal inflammation.27 Vitamin D deficiency has
been linked to reduced expression of VDR in the intestine, intestinal inflammation and
permeability in patients with inflammatory bowel disease.28 In PLWH, vitamin D
deficiency prevalence ranges from 70 to 85% in U.S.25,29 affecting not only compromised
immunity but also gut integrity in this population.
Studies on drug use have reported that 40% of PLWH used illicit drugs in the
preceding 12 months and 12% had screened positive for drug dependence.30–32 Cocaine is
considered one of the most addictive and abused illicit drugs among PLWH.33 Drug
abuse, particularly crack-cocaine, seem to accelerate HIV disease progression by
reducing CD4+ cell count and increase HIV viral load, promoting immunosuppression,
liver fibrosis, and altering microbiome composition in PLWH.34–38 The above evidence
may suggest that PLWH who use illicit drugs and have an impaired vitamin D status have
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higher risk for disruption of gut integrity, increased MT and immune activation.
However, no substantial evidence exists to show association among gut integrity, MT,
immune activation, inflammation and vitamin D status in the context of drug abuse
among PLWH. This study examined these associations providing evidence for the
development of adjunct therapies for the management of the co-occurring HIV and illicit
drug abuse, gut health and nutrition. To the best of our knowledge, this is the first study
assessing relationship among gut integrity, MT, immune activation, inflammation and
vitamin D status in cocaine users living with HIV.
Significance of the study
Several lines of evidence showed that HIV poses unfavorable consequences for
GI mucosa promoting MT and immune activation.18–21 Chronic and persistent immune
activation is documented to be a reliable predictor of HIV disease progression regardless
of ART use.39,40 Illicit drug abuse, particularly cocaine, worsen the immune system and
deteriorates nutritional status during HIV infection.41–43 Vitamin D deficiency is highly
prevalent among PLWH25,29 and due to its relationship with gut integrity, some studies
have shown association among vitamin D deficiency, MT and immune activation in
PLWH.44–47
Currently, understanding the interactions of multiple elements that promote
immune activation and inflammation continue to be a major goal toward improving
health and lifespan in PLWH. Therefore, this study is significant because it assessed the
relationships among key elements such as gut integrity, MT, immune activation,
inflammation and vitamin D status in drug users living with HIV, which eventually could
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postulate new strategies to target cocaine abuse, gut health and nutrition as important
factors in the management of immune activation and inflammation during HIV.
The evidence from the literature generates the following questions:
§

Is cocaine use associated with MT, immune activation, and inflammation among
PLWH despite ART use and virologic control?

§

Is cocaine use associated with poor gut integrity among PLWH despite ART use
and virologic control?

§

Is cocaine use associated with an impaired vitamin D status among PLWH?

Innovation
There is enough scientific evidence that support the mechanisms behind MT and
immune activation as key factors for HIV disease progression.39,40 The role of vitamin D
in gut integrity and immune system in HIV infection is less known25 despite deficiency of
this essential vitamin being highly prevalent in this population.29 However, the interplay
among MT, immune activation, inflammation and vitamin D status in the context of drug
abuse have not been investigated. To the best of our knowledge, this is the first study
incorporating cocaine abuse as a key player in the deterioration of gut integrity, MT,
immune activation, inflammation and vitamin D status in PLWH, which ultimately could
provide additional evidence to support the development of therapies to target gut health
and substance abuse programs to ameliorate the persistent immune activation and
inflammation among PLWH.
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AIM FOR CHAPTER III: ASSOCIATIONS BETWEEN MICROBIAL
TRANSLOCATION, IMMUNE ACTIVATION AND VITAMIN D STATUS IN
DRUG USERS LIVING WITH HIV
Specific Aim 1: to assess markers of MT, immune activation and vitamin D status in
cocaine users living with HIV.
Hypothesis 1a: Cocaine users living with HIV will have higher levels of MT, as
measured by Lipopolysaccharide (LPS), and immune activation as measured by sCD14,
sCD163 and sCD27, than cocaine non-users living with HIV.
Hypothesis 1b: Cocaine users living with HIV, who have vitamin D deficiency or
insufficiency, will have higher levels of MT, as measured by Lipopolysaccharide (LPS),
and immune activation as measured by sCD14, sCD163 and sCD27, than cocaine nonusers living with HIV
AIM FOR CHAPTER IV: MICROBIAL TRANSLOCATION, COCAINE USE
AND OBESITY ARE ASSOCIATED WITH INFLAMMATION AMONG DRUG
USERS LIVING WITH HIV
Specific Aim 2: To assess markers of inflammation and vitamin D status in cocaine users
living with HIV.
Hypothesis 2a: Cocaine users living with HIV will have higher levels of
inflammation, as measured by IL-6, TNF-α and high sensitive C-reactive protein (hsCRP) than cocaine non-users living with HIV.
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Hypothesis 2b: Cocaine users living with HIV, who have vitamin D deficiency or
insufficiency, will have higher levels of inflammation, as measured by IL-6, TNF-α and
high sensitive C-reactive protein (hs-CRP) than cocaine non-users living with HIV
AIM FOR CHAPTER V: GUT INTEGRITY, INTESTINAL INFLAMMATION
AND VITAMIN D STATUS IN DRUG USERS LIVING WITH HIV
Specific Aim 3: To assess marker of gut integrity and vitamin D status in cocaine users
living with HIV.
Hypothesis 3a: Cocaine users living with HIV will have reduced gut integrity, as
measured by Intestinal Fatty Acid Binding Protein (I-FABP), Interleukin 17 (IL-17), and
Interleukin 22 (IL-22) than cocaine non-users living with HIV.
Hypothesis 3b: Cocaine users living with HIV, who have vitamin D deficiency or
insufficiency, will have reduced gut integrity, as measured by Intestinal Fatty Acid
Binding Protein (I-FABP), Interleukin 17 (IL-17), and Interleukin 22 (IL-22) than
cocaine non-users living with HIV.
Sample Size
The study recruited 100 participants from the Miami Adults Studies in HIV
(MASH) Cohort Study in the FIU-Borinquen Research clinic who are currently
participating in an observational study, which investigates the impact of cocaine use on
HIV infection, HIV/HCV co-infection and long-term morbidity with a focus on liver
disease, directed by P.I. Dr. Marianna K. Baum.
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Statistical Analyses
Table 1 describes the dependent and independent variables and statistical analyses
conducted in each chapter for all hypotheses.
Table 1. Statistical Analyses of Hypotheses
Hypothesis
Dependent Variable
Chapter III
Hypothesis 1a

Independent variables

Statistical Analyses

Cocaine use, gender, age,
CD4 T cell, HIV viral
load, BMI

T-test for independent
samples, multiple linear
regression, Pearson
correlation

Cocaine use, gender, age,
vitamin D status, obesity,
seasonality

T-test for independent
samples. Logistic
regression

Inflammation as
measured by IL-6,
TNF-a and hs-CRP

Cocaine use, gender, age,
CD4 T cell, HIV viral
load, BMI

T-test for independent
samples, multiple linear
regression, generalized
linear model. Pearson
correlation

Inflammation as
measured by hs-CRP
>3mg/dl

Cocaine use, gender, age,
vitamin D status, obesity,
seasonality

T-test for independent
samples. Logistic
regression

Gut integrity as
measured by I-FABP
levels, IL-17 and IL-22

Cocaine use, gender, age,
CD4+ T cell count, BMI

T-test for independent
samples, multiple linear
regression, Pearson
correlation

Gut integrity as
measured by I-FABP
above median

Cocaine use, gender, age,
CD4+ T cell count, BMI,
vitamin D status

T-test for independent
samples, logistic
regression, generalized
linear model

MT levels as measured
by LPS
Immune activation as
measured by sCD14,
SCD27 and sCD163

Chapter III
Hypothesis 1b

MT levels as measured
by LPS above median
Immune activation as
measured by sCD14,
SCD27 and sCD163
above median

Chapter IV
Hypothesis 2a

Chapter IV
Hypothesis 2b
Chapter V
Hypothesis 3a
Chapter V
Hypothesis 3b
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CHAPTER II: LITERATURE REVIEW
Gut integrity
The mucosal barrier is considered a complex anatomical structure that separates
the internal milieu from the luminal intestine.1,2 This anatomical structure represents a
physical barrier with a cellular component that is essential for protection and function of
the intestine. Intestinal barrier and intestinal permeability address different aspects of the
mucosal barrier.2 It constitutes a structure that divides intestinal lumen from the internal
host in order to provide a shield against microorganism invasion.3 The barrier contains
mechanical elements (mucus and epithelial cell layer) and humoral and immunological
factors (immunoglobulin A, lymphocytes, innate immune cells).3
Intestinal permeability, on the other hand, is known to be a measurable feature of
the intestinal barrier,2 that in a sense, represents the level of diffusion through the
intestinal wall of large molecules. It has been shown that when the intestinal barrier is
damaged, intestinal permeability increases, allowing translocation of bacterial products
into the portal vein, causing endotoxemia and inflammation.2 Intestinal epithelium is a
key element of the intestinal barrier. It consists of a single-cell layer structure with an
estimated surface area of 30 m2 that maintains gut homeostasis, provides protection
against pathogens, and plays a central role in intestinal immunity.4–6
The intestinal epithelium structure has a high cell turnover activity, renewing its
cells every week. This cell renewal and differentiation is controlled by intestinal Cluster
Differentiation T helper Cells (CD4+ T).4,7 Cells composing the intestinal epithelium
may be differentiated into 4 cell lineage including absorptive cells or enterocytes, Goblet
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cells that produce mucus, chemokines and cytokines, entero-endocrine cells that produce
hormones, and Tuft and Paneth cells that manage mucosal immunity response.8,9
The intestinal immune system is considered a specialized and multifaceted
structure that has a substantial amount of organized lymphoid tissue. It contains more
lymphocytes than any other anatomical area in the body, particularly CD4+ T cells.4,10 As
mentioned previously, CD4+ T cells play a critical role in intestinal cell renewal and
pathogen elimination.11 Cells in the lamina propia synthetize immunoglobulin A which
helps in recognition of bacteria, and innate lymphoid cells that provide a defense line
against microorganisms.4,10 These elements of the intestinal immune system are called
gut-associated lymphoid tissues (GALTs).
Preserving gut integrity is a vital task for the intestinal epithelium. Tight junctions
are considered crucial elements that maintain gut integrity and intestinal permeability.
Tight junctions are proteins located in the paracellular spaces in the gut, allowing the
passage of water, nutrients and small molecules but blocking access for bacteria and
toxins.2
The tight junction complex is comprised of many transmembrane and cytosolic
proteins, including occludin, claudins, zonula occludens (ZOs), tricellulin, and junctional
adhesion molecules, which work together to preserve gut integrity.12,13 Tight junction
complexes are programmed to rapidly expose and seal the intestinal epithelium in the
occurrence of injury.14
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Regulation of gut integrity
The tight junction proteins are controlled by various signaling proteins and
molecules. Several molecules including small GTP-binding proteins, tyrosine kinases,
and protein kinase C, play an important role in the protection of tight junction integrity.14
Cytokines seem to also regulate tight junction protein during chronic diseases. Tumor
necrosis factor-α (TNFα) is a key regulator that negatively affects the expression of
occudins, promoting gut permeability.14 In addition, modulation of the intestinal
permeability is controlled by diet, short-chain fatty acids, prebiotics, probiotics and the
microbiome.2 The influence of diet depends upon host’s genetic susceptibility and
microbiome composition. However, studies have revealed that high fat15 and high sugar
diets, particularly high in fructose,16 have the ability to create a dysbiosis in the
microbiome, increase intestinal permeability and subsequent microbial translocation.
These processes are now being accepted as key factors for the development of chronic
diseases such as type II diabetes, non-alcoholic fatty liver, and cardiovascular diseases.16–
21

Among micronutrients, vitamin A and vitamin D play a critical role in the protection of

gut integrity.2,22

Marker of Gut Integrity
Intestinal Fatty Acid Binding Proteins (I-FABP) are small water-soluble proteins
found in mature enterocytes in both small and large intestines.2 These proteins transport
fatty acids from the apical membrane of the enterocyte to the endoplasmac reticulum
where lipid synthesis takes place.2 I-FABP is found in jejunum and it has been proposed
as a good biomarker to measure epithelial cell integrity, particularly in celiac patients.23
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In the event of intestinal damage, I-FABP is leaked into systemic circulation and elevated
levels indicate intestinal epithelial damage;2 reference values for healthy individuals are
considered 2 ng/mL or less in circulation.24 It can be measured in plasma and urine
implementing an Enzyme Linked Immunosorbent Assay (ELISA). Therefore, I-FABP
has emerged as a possible non-invasive marker for evaluating gut integrity loss and
intestinal inflammation.25

Effects of HIV on the Gastrointestinal Tract
The gastrointestinal (GI) tract mucosa is considered one of the most active and
important tissues of the immune system. The anatomical, histological and physiological
characteristics of the GI mucosa provide a barrier against microorganisms. The
enterocyte is the basic unit of the GI mucosa, serving as the single layer of cells for
absorption of nutrients, water, and protection from external pathogens. Therefore,
preserving the integrity of the GI mucosa is an essential task for the human body and the
immune system.26
Studies have shown that People Living with HIV (PLWH) have histological
abnormalities in the lamina propia of the enterocyte suggesting the occurrence of
pathologic processes induced by HIV. These abnormalities are mainly due to the
infiltration of lymphocytes, reduction and atrophy of the villus, and enlargement of the
intestinal crypts. The histological changes can be observed in the early stages of the
infection provoking the characteristic GI symptoms of HIV infection, such as diarrhea,
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increased intestinal permeability, intestinal inflammation, bloating, malabsorption of bile
acids and of vitamin B12. 26–29
HIV has been shown to directly affect the enterocytes due to the action of its
accessory protein Transactivation of transcription (Tat) that seems to inhibit the uptake of
glucose into the enterocyte. In addition, the envelope glycoprotein gp120, promotes
calcium accumulation inside the cell affecting the ionic homeostasis, 30,31 and activates
the intestinal immune system with the release of pro-inflammatory cytokines such as
TNF-a causing apoptosis, and interferon (IFN)-ƴ, interleukins (IL-12, IL-8 and IL-6),
which promote microbial translocation.32,33
The local immune activation of pro-inflammatory cytokines leads to
gastrointestinal CD4+ T destruction across the intestine and represents one of the major
sites for HIV replication.34,35 Studies have shown that CD4+ T cells in the GI tract are 10fold more frequently infected by HIV than are the cells in the blood, suggesting that the
GI tract is one of the largest HIV targets and an HIV reservoir in the human body.4,26,36–38
The loss of CD4+ T cells in the GI lamina propia, promotes a massive depletion of T
helper 17 (Th17) cells in the intestine that are responsible for the intestinal homeostasis,
mucosal regeneration and integrity.39,40
CD4+ T cells are the preferred target for HIV. These T cells are located in greater
amounts in the GI tract and lymphoid tissue than in peripheral blood. A study
investigated CD4+ T cells depletion in peripheral blood, lymphoid tissue and GI tract of
naïve PLWH and healthy controls. Blood samples to assess Peripheral Blood
Mononuclear Cells (PBMCs), inguinal lymphoid tissue, ileal Peyer’s patches and lamina
propia samples from the terminal ileum through biopsies were collected. There was a
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profound CD4+ T cells depletion in naïve PLWH in early stages of the disease.41 Also, it
was shown that the depletion was greatly observed in a subtype of CD4+ T cells that
expresses the C-C chemokine receptor type five (CCR5) which were mainly found in the
GI tract. The CCR5 is a co-receptor of the CD4+ T cell that facilitates the entry of the
HIV inside the cell. The HIV’s gp120 membrane protein attaches to the CCR5 protein
due to the tyrosine and acidic residues of the N-terminal, forming a strong chemokine
binding that ultimately promotes the entry of the HIV into the host cell.42 Thus, CCR5
CD4+ T cell can be considered a marker for CD4+ T cell depletion in the GI tract.41 In
fact, a decrease in intestinal CD4+ T cells (less than 200 cells/ µl) has been linked to the
incidence of diarrhea and opportunistic infections in PLWH.43

Effects of Antiretroviral Therapy in the Gastrointestinal Tract
Antiretroviral Therapy (ART) is considered the first line of treatment for HIV
infection. ART is able to reduce viral load to undetectable levels in peripheral blood
creating an opportunity for CD4+ T cell synthesis, and therefore, decreasing mortality
and morbidity among PLWH.44 It may be expected that the beneficial effects of ART
appear in other tissues besides peripheral blood. Previous data demonstrated that ART
was capable of ameliorating GI symptoms associated with HIV enteropathy in early
stages of the infection.45 Studies examining long term effects of ART on GI CD4+ T cell
reconstitution by immunohistochemistry and flow cytometry techniques, however,
demonstrated that CD4+ T cell in the GI had a slower rate of reconstitution than
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peripheral blood cells. Also, poor reconstitution of CD4+ T cell in the GI tract promoted
immune activation and debilitated the mucosal repair system.46–48
The mechanism behind poor CD4+ T cell reconstitution in the GI tract has not
been elucidated completely. One possible explanation may be that viral replication still
occurs at low levels in GI tract, preventing rapid CD4+ T cells reconstitution. A study
analyzing viral replication in rectal biopsies of PLWH found that CD4+ T cells continued
to produce the virus even after long term exposure to ART.49 It has been contemplated
that although the intestinal tract has a vast supply of blood, the apical surface of the
epithelial cells in both small and large intestines exhibit multi-drug-resistance proteins or
“toxin pumps” that decrease the bioavailability of the ART in the intestine allowing the
virus to replicate at low but continuous levels.26,50
Another possible explanation for the poor CD4+ T cell reconstitution in the GI
tract is the ongoing local inflammation. Local inflammation promotes fibrotic deposition
of collagen in the Peyer’s patch damaging the physical structure of the cell and making
CD4+ T cell reconstitution difficult.26,43 Therefore, long-term effects of ART on GI tract
produce poor CD4+ T cell reconstitution when comparing to the recovery in the
peripheral blood. Thus, even in patients, who comply with ART and have undetectable
HIV viral load in their blood, the intestinal CD4+ T cells recovery is incomplete,
bacterial translocation continues, and promotes immune activation, diminishing ability of
the intestinal mucosal to be repaired.46–48 As many as 30% of PLWH on ART fail to
reconstitute CD4+ T cells in the GI tract, despite having undetectable viral load in the
peripheral blood; these patients have been labeled “immunological non-responders”
(INRs) with faster HIV disease progression.43
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Recently, some researchers have raised a concern about the effects of ART on gut
microbiome as another possible mechanism that contributes to HIV enteropathy. It has
been proposed that protease inhibitor-based regimens pose the most dangerous effect to
the microbiome because this type of ART induces greater intestinal epithelium damage,
Microbial Translocation (MT), immune activation and inflammation than other regimes
such as nonnucleoside transcriptase inhibitors and integrase strand transfer inhibitors.51–53

Effects of HIV on Microbiome
Microbiome or microbiota is a term related to all population of microorganisms
that colonize a particular area in the body; the term not only includes bacteria but also
other microorganism such as viruses, fungi, archaea and protozoans 54,55
One of the critical roles of the microbiota in the intestine is the digestion of
insoluble fiber and synthesis of important metabolites such as short-chain fatty acids that
serve as energy for the enterocytes, which is important for immunomodulation.54 Also,
the microbiota enhance the connection between the intestinal tissue and the immune
system, specifically in the GALTs.56 The composition and diversity of the gut microbiota
is influenced by numerous factors such as age, diet, geography, antibiotic use and chronic
diseases, including HIV infection.54,55
The microbiome diversity appears to be reduced during HIV infection.57,58 Studies
have shown stools and mucosal biopsy samples of PLWH on ART and those who are
ART naïve to have greater abundance of Prevotella and reduced amount of
Bacteroides.39,54,56,59 Prevotella belongs to the phyla Proteobacteria that also includes
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pathogenic microorganism such as Shigella, Salmonella and Helicobacter, Pseudomonas,
and Acinetobacter that lead to the development of diarrhea, opportunistic infections and
production of Lipopolysaccharide (LPS). These bacteria play a major role in MT, and
immune activation during HIV-infection.57,59–61 On the other hand, Bacteroides derived
from the phyla Bacteroidaceae, including Lactobacillus ssp, offer anti-inflammatory
protection in the gut, and have been found to be reduced in PLWH.39,56,60,62,63

Microbial Translocation in HIV infection
It has been well established that humans and the microbiome have a symbiotic
relationship based on mutually beneficial interactions that maintain both the homeostasis
of humans and of the microbiome.64 The combination of reduced intestinal CD4+ T cells
and alterations in the microbiome lead to MT during HIV infection. Translocation of
bacteria is defined as the passage or transport of the microflora or its products from the
GI tract into the systemic circulation without causing bacteremia.65,66
The transport of the bacterial products follows a complex mechanism where they
have to cross the luminal mucosa, immunoglobulin A and the epithelial barrier, escape
from the macrophages in the GI lamina propia, and finally elude liver-mediated clearance
by the liver sinusoidal endothelial cells, Kupffer cells, and liver associated
lymphocytes.64 The causes of MT are diverse, these include: low level of
immunoglobulin A and enterotoxins from pathogenic species such as Vibrio, Escherichia,
Salmonella, Helicobacter, Clostridia and some viruses, including HIV, that generates
disruption of the gut integrity.64
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The harmful effects of the HIV enteropathy is highlighted by the extensive
depletion of the CD4+ T cells in the GI tract, poor mucosal reconstitution, physical
destruction of the epithelial barrier, increased permeability and local inflammation, which
pose a risk for MT and immune activation.32–35,67,68 Studies have demonstrated that
products of MT, specifically LPS in the circulation induce T-cell activation which is
considered a hallmark in predicting clinical outcomes of HIV infection.69–73 These
findings were based on an early research conducted by Funderburg et al.69 who assessed
the effects of microbial Toll-like receptors (TLR) ligands on T-cell activation in healthy
individuals (n=20). It has been established that TLR ligands recognize MT products in
the systemic circulation as demonstrated in an in vitro study, with PBMC’s exposed to
either plate-bound-anti-CD3 monoclonal antibodies or TLR ligands. TLR ligands induced
T-cell activation, particularly CD4+ and CD8+ T cells and TLR ligand exposure
promoted CD4+ T cell apoptosis. It was also concluded that TLR are important sensors
for innate immune response in healthy controls.69 This was the first study that proposed a
model mechanism behind MT and the pathogenesis of HIV infection.

Markers of Microbial Translocation
Microbial translocation can be measured by direct markers including LPS and
bacterial DNA or RNA fragments, and indirect makers such as Lipopolysaccharide
Binding Protein (LBP) and Endogenous endotoxin-core antibodies (EndoCAb).66 Once
these by-products of MT are in the systemic circulation, they induce inflammatory
responses by stimulating a number of cell-surface receptors, including nucleotide-binding
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oligomerization domain 1 (NOD1), NOD2, Toll-like receptor 2 (TLR2), TLR4, TLR5,
TLR6 and TLR9, and soluble CD14 (sCD14), which are expressed in many cell types of
the innate immune system.74
The innate immune system cells, monocytes, macrophages and dendritic cells,
become activated by the products of MT, initiating a cascade of pro-inflammatory
cytokines such as interleukin 1-β (IL-1β), IL-6, TNF-a and type I interferons.74
Lipopolysaccharide (LPS) is the most important component of the outer
membrane in Gram-negative bacteria and a strong stimulator of the innate immune
system. LPS is composed of a poly or oligosaccharide that is attached to outer bacterial
membrane by a specific carbohydrate lipid moiety, lipid A, considered the factor that
stimulates the immune system75 and has been suggested as the major marker for MT, as it
activates the cellular complex of LPS binding-protein (LBP), sCD14 and TLR4
(TLR4*MD-2 complex) that initiates inflammatory response.66,75
Efforts have been made in the scientific community to establish the relationship
among MT markers during HIV infection. In this regard, one study investigated the
correlation between MT markers in PLWH (n=18) with controlled viral load and exposed
to ART. Blood samples were collected to assess LPS, LBP, sCD14 and 16S rRNA at
baseline and different time points.
Researchers found a significant association between LPS and sCD14 (r=0.407,
P<0.001) and LPS and LBP (r=0.260, P=0.042). These findings indicated that LPS
correlates well with other biomarkers of MT, LBP, and immune activation, and it serves
as a good marker for MT during HIV infection.76
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Immune Activation in HIV infection
Immune activation is defined as a phenomenon characterized by complex
processes that stimulate and activate the immune system creating constant
inflammation.77 During the course of certain diseases, including HIV, acute inflammation
persists, and generates chronic inflammation with continuous activation of cells and
cytokines, which can be stimulated for years under low-grade inflammation or immune
activation.78
HIV infection activates both innate and adaptive immune responses, and
therefore, immune activation. Once HIV has entered to the human body, it activates the
innate response from dendritic and natural killer cells. It had been found that the loss of
dendritic cells causes decrease in Interferon alpha (INF-α) production, an important
cytokine, is due to increased viral load during HIV infection.71,79 In addition, natural
killer cells protect the body from HIV replication by eliminating HIV infected cells,
which provoke cytokine liberation, particularly IFN-ƴ, TNF-α and β-chemokines (CCL3,
CCL4 and CCL5). 80
Simultaneously, the adaptive immune response is triggered, especially with the
activation of CD4+ T and CD8+ T cells. Helper T cells or CD4+ T cells are the preferred
target of HIV. Once HIV infects CD4+ T cell, it induces apoptosis probably due to the
action of the virus proteins gp120, Tat, Nef and Vpu, causing massive loss of these
cells.71,77 The CD4+ T cells provoke the release of a numerous cytokines that can
determine disease progression. Pro-regulatory cytokines, (Th1 type) including interleukin
2 (IL-2), IL-12 and IFN-ƴ, up-regulate HIV virus replication in infected cells while proinflammatory cytokines (Th2 type) such as IL-4, IL-10, IL-5, IL-3 induces more
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inflammation during HIV infection.78 It has been suggested that during HIV infection
there is an imbalance between cytokines, with an overproduction of Th2 type and
underproduction of Th1 type contributing to immune activation.81 The constant
stimulation and activation of the CD4+ T cells and cytokines by HIV, induces the
expression of CCR5 receptors that predispose more CD4+ T cells to become infected,
creating a vicious cycle, in which infection causes immune activation and leads to a
massive CD4+ T cell depletion.82
Besides the cytopathic effects of HIV on CD4+ T cells, there are additional
consequences including proliferation, expansion and death of non-infected CD4+ T cells
that creates an increased T-cell turnover, and ultimately the collapse or exhaustion of the
regenerative capacity of the entire immune system.83,84 The high T-cell turnover is
directly associated with the level of viremia and CD4+ T cell loss,85 which are the
hallmarks for HIV disease progression in the absence of ART.86 Studies show that
immune activation and inflammation persist even after long-term ART exposure and
sustained viral suppression, which eventually promotes a rapid disease progression.87–89

Markers of Immune Activation
Soluble CD14 (sCD14) is a co-receptor localized in peripheral blood monocyte
and tissue macrophages. Once LPS is in the systemic circulation, CD14+
monocyte/macrophages release sCD14 to be linked to the LPS molecule and initiate
inflammatory response; sCD14 also works in conjunction with LBP and TLR4 to activate
the TLR4*MD-2 complex and induce the inflammatory response.64,73 sCD14 can be
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measured in plasma and it correlates very well with LPS.66 It has been suggested that
sCD14 can also be activated by other factors such as TLR ligand flagellin and
inflammatory cytokines including IL-6 and IL-1β indicating that sCD14 is a marker of
monocyte activation that is not exclusively due to LPS stimulation.90 Studies have shown
that increased levels of sCD14 may be associated with chronic diseases among PLWH
including preclinical atherosclerosis,91 hypertension,92 and hepatitis C,93 as well as
neurocognitive impairment.94 In addition, this biomarker was found to be associated with
6-fold increased risk of all-cause mortality among PLWH.74
Soluble CD163 (sCD163) is considered another marker for monocyte activation
and innate immune response associated with the hemoglobin scavenger receptor.95
Studies have suggested that high sCD163 levels are present in tissue macrophages
indicating not only immune activation but tissue inflammation during HIV infection;96
also, high sCD163 levels had been associated with neurocognitive impairment,97
cardiovascular diseases98 and mortality among PLWH.99
Soluble CD27 (sCD27) is considered to be a marker for T cells and the adaptive
immune response95 during HIV infection.100 Its structure consists of a glycoprotein that
belongs to pro-inflammatory cytokine TNF receptor family and it is presented on the
surface of some T cells.95 Levels of sCD27 correlate with IgG concentrations among
PLWH. Even in patients on ART, elevated levels of sCD27 continue101 and are
associated with the development of neoplastic diseases such as non-Hodgkin lymphoma
in PLWH on ART.95
Cytokines are a group of proteins secreted by the immune system, mainly T cells
and macrophages. The main purpose for cytokines is to facilitate cell signaling, cell to
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cell communication in immune response and the migration of cells to sites of
inflammation.102 Cytokine is considered a general term that groups lymphokine (cytokine
made by lymphocytes), chemokines (cytokine with chemotactic effects that attracts
leukocytes to site of inflammation), monokines (cytokines made by monocytes) and
interleukin (cytokines made by one leukocyte that acts on other leukocytes).102 Cytokines
have a cascade effect and can act synergistically as messengers of the immune system.
Cytokines can be classified as pro-inflammatory and anti-inflammatory. Proinflammatory cytokines are usually produced by macrophages in response to
inflammation.102

Markers of Inflammation
Interleukin 6 (IL-6) is produced by monocytes, macrophages and T-lymphocytes
in response to inflammation. It is involved in T cell growth, proliferation and
differentiation and it acts in conjunction with IL-1β and TNF-α to enhance inflammatory
response. It is also believed that IL-6 promotes HIV replication103,104 since IL-6 is
abnormally high during HIV infection causing detrimental consequences to the host.105
Interleukin 17 (IL-17) is produced by Th17 cells and helps to regulate the
inflammatory response by activating macrophages and neutrophils to improve their
recruitment and survival.106,107 Studies revealed that IL-17 levels are particularly high
during HIV infection;106 however, in another study it was demonstrated that the levels of
IL-17 in the GI tract were decreased due to depletion of Th17 cells and CD4+ T cells
when the virus infects the GI tract.26 Low levels of IL-17 promote bacterial infections,
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MT, and ultimately it is considered a strong predictor for immune activation and HIV
disease progression.64,108
Interleukin 22 (IL-22) is produced by Th22 cells and plays a critical role in
preserving the innate immunity in the intestine, protecting from bacterial infections and
inflammation, as well as improving intestinal epithelium repair.109,110 A study
demonstrated that sigmoid IL-22-producing T cells and Th22 cells were severely
depleted during chronic HIV infection, epithelial integrity was compromised, and MT
was increased.111
Tumor Necrosis Factor alpha (TNF-α) is a protein secreted by many cells of the
immune system including monocytes, macrophages, T and B cells, NK cells among
others. TNF-α is a potent inflammatory cytokine that has 2 main receptors: soluble TNF
receptor 1 and TNF receptor 2 that inhibit the effects of the TNF-α.104 During HIV
infection, TNF-α stimulates viral replication, therefore, plasma levels in untreated PLWH
are high and are highly correlated with disease progression.103,104,112
The acute phase C-reactive protein is a well-known marker for inflammation and
tissue damage that is the consequence of acute and chronic infections. CRP levels change
in response to other pro-inflammatory cytokines such as IL-1 and IL-6.113 Studies have
demonstrated that high sensitive CRP (hs-CRP) levels were particularly higher in PLWH
when compared with healthy population and that hs-CRP is a good inflammatory marker
in HIV disease and shows the risk for other comorbidities, including cardiovascular
diseases.114,115
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Microbial translocation and immune activation in HIV disease progression
Immune activation is considered of the best predictors to assess HIV disease
progression. It has been demonstrated the MT induces massive immune activation in
PLWH.65 In an earlier study, researchers examined the relationship between MT and
immune activation in PLWH (n=205) and uninfected participants (n=47). Blood samples
were collected to assess LPS using Limulus Amebocyte assay. Soluble CD14 and
Interferon alpha (IFN-α) were determined with ELISA assays as markers of immune
activation. In this study, PLWH had significantly higher levels of plasma LPS than
uninfected participants (P<0.001) indicating the presence of microbial products in
systemic circulation. Immune activation was found higher in PLWH with elevated
plasma sCD14 levels (P<0.0001) than uninfected participants; there was a positive
correlation between LPS and sCD14 (r=0.3, P=0.001) and LPS and IFN-α (r=0.624,
P<0.0001) indicating that MT induces immune activation in PLWH.116
In another study, Dinh et al.117 evaluated microbiota composition, MT and
systemic inflammation in PLWH on ART with undetectable viral load (n=21) and healthy
controls (n=16). Stool and blood samples were collected. Phylogenetic diversity, MT
markers including Endotoxin core immunoglobulin M (EndoCAb IgM), sCD14 and LPS
were measured with ELISA and Limulus Amebocyte assays respectively, plasma 16S
rRNA gene levels were determined with quantitative real-time PCR; immune activation
markers: IFN-ƴ, interleukin 1-β (IL-1β), interleukin-6 (IL-6), TNF-α and hs-CRP were
measured. This study found that PLWH had predominantly Probacteria, Enterobacteriales
and Enterobacteriacea counts and decreased Rikenellaceae and Alistipes compared to
healthy controls indicating a microbiome dysbiosis in PLWH. Plasma sCD14 levels were
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significantly elevated in PLWH when compared to healthy controls (P<0.001); EndoCAb
levels were significantly reduced in PLWH (P<0.001) since this molecule binds LBP
increasing LPS levels. High LPS levels were found in PLWH, however, it was not
significant (P=0.08), as well as high plasma 16S rRNA levels. As expected, PLWH had
immune activation with elevated IL-1β and TNF-α (P=0.02 and P=0.03, respectively).
The products of MT induced immune activation as LPS were positively correlated with
IL-6 (P<0.001), TNF-α (P<0.001) and hs-CRP (P=0.01) in PLWH despite ART use and
viral suppression.117
Findings from other studies in PLWH with long exposure to ART showed that
MT improved CD4+ T cell reconstitution and promoted immune activation.87,118,119 This
suggests that MT and immune activation could be independent factors that promote
damage of the GI tract during HIV infection despite ART and viral replication.
Immune activation has been identified as one of the factors that increase
morbidity and mortality among PLWH regardless of viral suppression and ART use.
Constant low levels of virus replication from reservoirs, particularly GI tract, are kept
despite ART use. Co-infection with other viruses such as hepatitis C exponentially
enhances immune activation during HIV infection.72 This creates a vicious cycle where
gut barrier immunity is compromised by the HIV promoting MT and immune activation,
and ultimately disease progression.
Hunt et al.120 assessed immunological predictors of mortality during HIV
infection in a case-control study. Participants were recruited from the Longitudinal Study
of the Ocular Complications of AIDS (LSOCA) a multicenter cohort of PLWH who
started ART treatment with AIDS diagnosis. PLWH who died (not to be known

31

accidental) within 12 months of ART exposure (n=64) were matched to 2 controls (total
number of controls 128) by duration of ART, CD4+ T cell levels, age, sex and prior
opportunistic infections. Plasma and PBMC’s samples were taken from prior visits and
analyzed. Researchers discovered that I-FABP and zonulin-1 (gut integrity biomarkers),
sCD14, soluble TNF-1 receptor, hs-CRP and D-dimer levels all strongly predicted
mortality, even after adjusting for CD4+ T cell levels (all P<0.001).120 These findings
support the idea of the need to further examine the damage to the gut barrier integrity and
MT during HIV infection and ART use.

Substance Abuse
Cocaine use
Cocaine is an alkaloid derived from the leaves of the coca plant Erythroxylum
coca. It is a potent vasoconstrictor and powerful stimulant of the brain which when
abused leads to several medical complications. Indeed, the effects of cocaine on the brain,
particularly the inhibition of the dopamine re-uptake, make cocaine one of the most
addictive and abused illicit drugs.121 Therefore, the National Institute of Drug Abuse
classified cocaine as a Schedule II drug with high potential for abuse.122 Cocaine can be
used orally, intranasal, intravenously and by inhalation. Cocaine users use cocaine in two
chemical forms: water-soluble hydrochloride salts, a powder that can be injected or
snorted; and the water-insoluble cocaine base, which is mixed with sodium bicarbonate
and water, and then heated to produce what is commonly called crack.122
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Cocaine use and Gut integrity
Several lines of evidence have shown that cocaine abuse poses detrimental effects
for GI tract including weight loss, malnutrition, anorexia and reduced blood supply to
enterocytes.123–125 The exact mechanisms behind the action of cocaine and deterioration
of the GI tract have not been fully elucidated.
However, studies suggested that cocaine has the ability to dysregulate the
expression of the tight junction proteins in the intestinal epithelium, promoting gut
integrity damage and hyperpermeability.124 A study conducted with rodents demonstrated
that alteration in gut microbiome seemed to potentiate sensitivity to cocaine reward and
locomotor effects, proposing a connection between gut microbiome and altered
behavioral responses to cocaine.126
A recent study with mice demonstrated that intraperitoneal administration of
cocaine created a microbiome dysbiosis and depletion of bacteria responsible for
producing short-chain fatty acids, key elements that provide energy to the enterocytes and
promotes microbiome diversity.127 Also, cocaine generated an inflammatory response in
the gut due to the release of pro-inflammatory cytokines (IL-18 and IL-1b).
Furthermore, in vivo and in vitro analyses demonstrated that cocaine upregulated
the expression of an important tight junction protein (claudin-2) promoting intestinal
permeability in the gut.127 This finding suggests that cocaine abuse poses dangerous
effects for gut integrity, intestinal inflammation and microbiome.
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Cocaine use and HIV disease progression
Epidemiological studies have demonstrated that active illicit drug use, particularly
cocaine, is associated with poor adherence to ART, reduced virologic and immunologic
control, HIV disease progression and mortality.128–130
Cocaine and its biological forms are one of the drugs of choice among PLWH. In
a study analyzing the illicit drug patterns among PLWH in 8 U.S. cities, it was found that
40% of participants had heavy alcohol consumption or crack-cocaine use in the preceding
12 months.131 Since cocaine use is highly prevalent among PLWH, several studies have
been conducted to examine the effects of cocaine use on HIV disease progression.
Cocaine has the ability to reduce CD4+ T count and increases HIV viral load in
PLWH. Baum et al.130 conducted a prospective, longitudinal study to evaluate the effects
of cocaine use on HIV disease progression in PLWH on ART (n=222). Blood was
collected every 6 months for 30 months to assess CD4+ T cell count and viral load, urine
toxicology and socio-demographic data were also collected. Crack-cocaine users were
2.14 times more likely to have a decline in CD4+ T cell count (≤200 cells/ml),
independent of ART use, than -cocaine non-users (95% CI: 1.08-4.25, P=0.029). Viral
load was significantly elevated among crack users (P=0.037) regardless of ART use.
Researchers concluded that crack-cocaine use promotes decline in CD4+ T cells count
and reduced medication adherence, which ultimately accelerates HIV disease
progression.130
Many studies have tried to elucidate mechanisms behind the toxic effects of
cocaine in CD4+ T cells.121,132–134 Cocaine seems to support HIV replication because it
facilitates the virus entry by upregulating the expression of the co-receptors CXCR4 and
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CCR5 on the membrane of the CD4+ T cells.135,136 Cocaine also enhances later steps in
HIV viral replication by inhibiting cellular miRNA “miR-125b” in CD4+ T cells, which
is responsible for inhibiting the HIV replication cycle.137 It has been shown that cocaine
induces CD4+ T cell apoptosis in cell culture studies due to an increase in oxidative
stress, particularly in the reactive oxygen species (ROS).138 In addition, cocaine has been
postulated as a potent immunosuppressant that alters the function of the cells of the
immune system.
Cocaine affects thymic endocrine function in PLWH, which plays a vital role on
immune recovery, by reducing the thymulin activity even in the presence of ART and
HIV viral load, contributing to the progression of the disease.139 Another study
demonstrated that cocaine users were 75 times more likely to have low thymulin activity
(OR= 74.7, 95% CI: 1.59- 3519.74, P= 0.002) and that thymulin activity was inversely
associated with cocaine use (β= -0.908, 95% CI: -1.704, -0.112, P= 0.026) independent of
ART use.139 This study suggested another possible mechanism that may predicts HIV
disease progression.

Cocaine use and microbiome during HIV infection
As discussed previously, cocaine has been associated with important
gastrointestinal disturbances including diarrhea, nausea, vomiting and anorexia that alter
the microbiome, as well as the use of antibiotic therapy.140 In addition, lifestyle pattern,
dietary choices, and nutritional status may affect the microbiome. 140 A cross-sectional
study investigated microbiome composition, MT, immune activation and nutritional
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status in drug users living with HIV (n=32) from the CARE study. Participants were
grouped into 4 arms: (1) PLWH, (2) healthy controls, (3) PLWH cocaine users and
healthy controls who used cocaine. Stool samples were collected to evaluate microbiome
alterations and diversity by 16SrRNA gene pyrosequencing. Blood was collected to
analyze markers of MT and immune activation. Dietary data were collected by 24-hour
recall. It was found that cocaine users had relative abundance of phyla Bacteroides and
Firmucutes suggesting a dysbiosis in the microbiome. As expected, sCD14 and TNF-α
were significantly higher in PLWH (P=0.01 and P=0.03, respectively). Cocaine users had
a lower Healthy Eating Index when compared to cocaine non-users.140 This study
suggests that cocaine use may cause alterations in microbiome, increased MT and
immune activation among PLWH.

Alcohol abuse
It has been well established that alcohol and its metabolites provoke disruption of
intestinal tissue homeostasis, intestinal inflammation, changes in microbiome, bacteria
overgrowth and destabilization of the local immune system.59,141–147 One of the most
devasting effect of alcohol in the intestine is the ability to destroy epithelial cell wall
causing trans-epithelial permeability, and the spaces between the epithelial cells
(paracellular permeability), which are represented by the tight junctions, cytoskeleton and
proteins.148,149 These events lead to cellular damage, destruction of gut integrity and
increased permeability, allowing passage of large molecules, including LPS, through
intestinal barrier,150,151 ultimately causing MT.
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Studies have reported that PLWH are twice more likely to consume alcohol than
healthy individuals.152 Hazardous alcohol drinking increases viral replication and
production of pro-inflammatory cytokines in PLWH.153 It is not surprising that alcohol
and its metabolites worsen the already disrupted GI tract in PLWH, contributing to the
ongoing local inflammation, MT and immune activation. Alcohol appears to induce
apoptosis in T cells through downregulation of the Vitamin D receptor (VDR),154–157
proposing a link between vitamin D deficiency and alcohol abuse in the context of HIV
infection.

Vitamin D
Vitamin D is a fat-soluble steroid derived from 7-dehydrocholesterol, a
cholesterol precursor.158,159 Vitamin D has two major forms that are important for human
health, ergocalciferol or D2 synthesized from ergosterol in plant sources, particularly
fungi, and cholecalciferol or D3 derived from cholesterol in animal products.158–160 The
main source of vitamin D3 in humans (80-90%)161 is made in the skin upon sun exposure
due to the irradiation of 7-dehydrocholesterol to pre-vitamin D3 at UVB wavelengths of
290-320nm, with a further isomerization to create vitamin D3.162,163
The remaining source of vitamin D (10-20%)161 is obtained through dietary
sources including: fish, eggs, oily fish (pink salmon, sardines, Mackerel), fortified foods
(milk, dairy products and breakfast cereals). Vitamin supplements are available in D2 and
D3 forms.161,163
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Vitamin D Metabolism
The active forms of Vitamins D2 (ergocalciferol) and D3 (cholecalciferol) are
synthetized by the action of enzymatic hydroxylation process, which occurs mainly in
liver.163 In the liver, vitamin D2 and D3 are converted into 25-hydroxivitamin D2
(25[OH]D2) and 25-hydroxivitamin D3 (25[OH]D3),160,161 respectively due to the action
of 25-hydroxylases, which belong to the cytochrome P450 group.163 In the kidneys, 25hydroxivitamin D is converted to its biologically active form 1,25-dihydroxyitamin D2
(1,25[OH]D2) or D3 (1,25[OH]D3) (calcitriol) by 1a-hydroxylase.161,163 The rate of
conversion depends upon circulating parathyroid hormone concentrations. Once
1,25[OH]D3 (calcitriol) is available, serum calcium and phosphate levels are regulated via
the control of calcium absorption in the intestine, renal resorption of phosphate, and
release of calcium from bones.162,163
A small proportion of vitamin D is transported in blood as “free” steroid and
access the cells via simple diffusion. The remaining vitamin D in blood is attached to
Vitamin D-binding protein (DBP).158,160 The DBP has strong affinity for 25[OH]D, and a
weak affinity for 1,25[OH]D (biologically active form).159 However, 1,25[OH]2D has
high affinity for VDR which provides access to gene transcription system inside cell.159
Importantly, vitamin D can also enter the cell throughout VRD localized in membrane to
execute its non-genomic effects such as modulation of growth factors and cytokines.164
VDR is found in many tissues and cells, especially in intestine, kidney, and immune cells,
which makes vitamin D a regulatory agent in the innate and adaptive immune
systems.165,166
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Also, the effects of vitamin D in combination with VDR on the immune response
is seen in other cells, including intestinal epithelial cells,167 demonstrating a role of
Vitamin D in gut integrity.

Vitamin D and Gut integrity
In vitro studies demonstrate that optimal levels of vitamin D3 is capable of
decreasing intestinal permeability and preserve gut integrity.168,169 One of the mechanism
of the protective role of vitamin D in the intestine is explained by signaling of VDR.170 It
seems that activation of VDR in the intestine regulates the intestinal Paneth cells which act
as antimicrobial host defense in the pathogenesis of Chron’s disease.171,172 In addition,
vitamin D3 induces the expression of occudin, zonula occludens (ZO) ZO-1, ZO-1 and
vinculin, which represent the major protein family expressed in intestinal tight junction,
that are in charge of sealing spaces among intestinal cells, representing the key element in
gut integrity.173–176
Several studies have shown the association of vitamin D and VDR in Intestinal
Bowel Disease (IBD).177 Vitamin D deficiency have been reported in patients with IBD,
and VDR protein was reduced in IBD and colitis-associated colon cancer patients.178,179
Therefore, adequate levels of vitamin D and subsequent expression of intestinal VDR are
essential to control intestinal homeostasis.
Studies suggested that vitamin D status is related to the function and composition
of the microbiome.180,181 Vitamin D3 is able to modify the composition of the intestinal
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microbiome in patients with IBD.182 Importantly, VDR regulate the immune response to
the microbiome and control microbiota dysbiosis.183

Vitamin D Deficiency in HIV infection
Vitamin D deficiency is considered one of the major public health issues
worldwide in all age groups;184–187 even in regions with appropriate UV radiation, and in
industrialized countries where typically vitamin D is supplemented.159,184 Data from the
National Health and Nutritional Examination Survey (NHANES) showed that vitamin D
deficiency and insufficiency were found in 33.5% and 71.1% of the US population
respectively in 2013-2014, and the prevalence was higher in disadvantage minorities.188
Numerous studies have suggested that vitamin D deficiency is linked not only to
bone disorders but to chronic diseases including cardiovascular disease,161 chronic kidney
disease,189 type II diabetes,190 metabolic syndrome, cancer and infectious diseases,
including HIV and hepatitis C infections.159,191–193
Epidemiological studies have shown that prevalence of vitamin D deficiency
among PLWH ranges between 70-85%.193,194 PLWH present similar risk factors for
vitamin D deficiency as healthy people including: gender (females have higher risk),
limited sunlight exposure, black ethnicity, advanced age, poor dietary vitamin D intake,
obesity, cardiovascular and renal disorders, diabetes mellitus, metabolic syndrome,
hepatic steatosis, and alcohol consumption.159,193,195–198 However, PLWH have additional
risk factors for vitamin D deficiency due to the action of HIV itself.159 It has been well
established that HIV promotes chronic inflammation and massive immune
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activation,81,199 and persons with vitamin D deficiency show an increase in proinflammatory cytokines, such as IL-6 and TNF-a,200 and monocyte activation, which are
considered key elements for HIV disease progression.
Chronic inflammation initiated by HIV alters the activity of 1a-hydroxylase in the
kidneys, which is the enzyme responsible for the conversion of 25(OH)D to the
biologically active form 1,25(OH)2D, causing a reduced production of the vitamin and
promoting deficiency.159,193,201
HIV-infected T cells have been shown to have attenuated expression of VRD
which impairs vitamin D effects.157,202 Also, ART use, particularly Protease Inhibitors
(e.g. Reyataz, Prezista, Rezolsta, Kaletra, Evotaz) lower the conversion of 25(OH)D to
1,25(OH)D,193,203 and non-nucleoside reverse transcriptase inhibitors (e.g. Sustiva,
Intelence, Viramune, Edurant) increase 25(OH)D catabolism.204 Conjointly,
comorbidities, infectious complications, hospitalizations and drug use by PLWH lead to
limited sunlight exposure, poor nutritional status, and reduced vitamin D intake,
contributing to risk of vitamin D deficiency.193,205,206

Vitamin D Levels: Measurements and Cut-Off Points
Measurement of 25(OH)D in serum or plasma is considered the fastest and most
accurate way to assess levels of vitamin D in body.159 Quantification of 25(OH)D is
preferred over 1,25(OH)2D due to lack of standardization methods (linearity, specificity,
the effect of anticoagulants).207 Also, 25(OH)D reflects vitamin D produced in the skin
and obtained from food and supplements,208 and it has a long circulating half-life of 15
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days, whereas 1,25(OH)2D has a very short half-life of 15 hours and serum
concentrations are tightly regulated by parathyroid hormone, calcium and phosphate.209
Levels of 1,25(OH)2D do not decrease until a severe vitamin D deficiency
occurs.210–212 In fact, a group of experts from the Vitamin D External Quality Assessment
Scheme (DEQAS), who participated in the Vitamin D Standardization Program,
recommended the use of the standardized laboratory measurement of 25(OH)D.213
There are two established methods to estimate vitamin D levels: competitive
immunoassays, including protein-binding and radioimmunoassay, which measure total
levels of 25(OH)D without differentiating 25(OH)D2 and 25(OH)D3; and those based on
high-performance liquid chromatography and direct detection with liquid
chromatography tandem-mass spectrometry (LC-MS/MS).185,214 The last two are highly
sensitive and allows for the quantification of both 25(OH)D2 and 25(OH)D3. However,
they are difficult to perform and require specialized technology.215 Vitamin D levels are
commonly expressed in nanogram per milliliter (ng/mL) or nanomole/liter (nmol/L).
According to the Endocrine Society Clinical Practice Guidelines, adequate levels of
vitamin D in adults are considered to be >30ng/mL (75nmol/L), insufficient levels 21-29
ng/mL (52.5-72.5 nmol/L) and deficient levels at <20 ng/mL (50nmol/L).185,216

Vitamin D Deficiency, MT and Immune activation in HIV infection
Several studies have elucidated the relationship between vitamin D deficiency and
MT. Garcia-Alvarez et al.217 conducted a cross-sectional study to assess the association
between 25(OH)D levels and MT as measured by the bacterial 16S ribosomal RNA in
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120 people living with HIV/HCV and found that 15% of the participants were vitamin D
deficient, while 77% were vitamin D insufficient. Low plasma levels of 16S ribosomal
RNA were found in 66.7% of participants with optimal levels of 25(OH)D. Also, low
plasma levels of CCL7, an inflammatory marker, were found in participants with optimal
levels of 55(OH)D suggesting that optimal vitamin D status was associated with low
levels of MT and inflammation in this population.217
Similarly, Missailidis et al.218 investigated the association between vitamin D
status, MT and inflammation in Caucasian men living with HIV (n=97) and controls
(n=30) in Sweden. In this cross-sectional study, researchers did not find association
between vitamin D levels and MT. However, PLWH had higher levels of immune
activation (sCD14) and inflammation (hs-CRP) (P<0.001 for both) than HIV negative
controls. Vitamin D deficient participants living with HIV had higher levels of IL-6 than
PLWH with adequate levels of vitamin D (P=0.003).218
Additional cross-sectional studies have focused on investigating link between
vitamin D status and inflammatory markers in PLWH. It was suggested that in PLWH on
ART, higher 25(OH)D levels were inversely correlated with levels of TNF-a (r=-0.20,
P=0.04), and adiponectin (r=0.30, P=0.002).219 In addition, another study demonstrated
that PLWH who had vitamin D deficiency had higher levels of inflammation as measured
by IL-6 (P<0.01), TNF-a (P=0.03), and increased immune activation as measured by
CD14dimCD16+ (P<0.01) and CX3CR1+ monocytes (P<0.001) than PLWH with
insufficient and sufficient levels of vitamin D.200
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Summary
Gut integrity is essential for the function and protection of the intestine. A chronic
alteration of the factors that modulate gut integrity can cause intestinal permeability, MT
and inflammation. One of the factors that can disrupt gut integrity is HIV infection. The
intestine is considered an important target for HIV because of the large presence of CD4+
T cells in this area. In fact, studies have shown that CD4+ T cells in the GI tract are 10fold more frequently infected by HIV than are the cells in the blood, suggesting that the
GI tract is one of the prominent HIV targets and reservoir in the human body.26,36–38 The
deleterious effects of the HIV enteropathy are highlighted by the extensive depletion of
the CD4+ T cells in the GI tract, poor mucosal reconstitution, physical destruction of the
epithelial barrier, increased permeability, inflammation and microbiome dysbiosis, which
pose a greater risk for MT and immune activation.32–35,57,58,67,68
Immune activation has been identified as one of the factors that increase
morbidity and mortality among PLWH, regardless of viral suppression and ART use.
Constant low levels of virus replication from reservoirs, particularly GI tract, continue
despite ART use, and enhance immune activation during HIV infection.72 This creates a
vicious cycle where gut barrier immunity is compromised by the HIV promoting MT and
immune activation, and ultimately facilitating disease progression.
Cocaine is associated with poor adherence to ART, reduced virologic and
immunologic control, HIV disease progression and mortality.128–130 In addition, cocaine
promotes dysbiosis in the microbiome, promotes MT and immune activation in
PLWH.140
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Vitamin D deficiency is highly prevalent among PLWH, especially in those with
comorbidities, infectious complications, hospitalizations and drug use, leading to limited
sunlight exposure, poor nutritional status, and reduced vitamin D intake, therefore,
contributing to risk of vitamin D deficiency.193,205,206 Importantly, it has been suggested
that beyond its classical roles in calcium homeostasis, vitamin D3 is capable of decreasing
intestinal permeability and preserve gut integrity.168,169
Some studies have suggested association of vitamin D deficiency and high levels
of MT, immune activation and inflammation in PLWH.200,217–219 However, these studies
were done with predominantly Caucasians men and illicit drug use was not investigated.
Gut integrity was not assessed in the context of vitamin D deficiency or insufficiency and
dietary intake data were not collected.
The role of cocaine in gut integrity, MT, inflammation and immune activation in
the context of vitamin D deficiency or insufficiency has not been examined. The evidence
shows that vitamin D is an essential nutrient for immunity and gut integrity, and its
deficiency is highly prevalent among PLWH. Therefore, it is critical to assess
relationships among gut integrity, MT and immune activation and inflammation in
cocaine users living with HIV, who exhibit vitamin D deficiency or insufficiency.
Building on the findings of others, our findings may help to elucidate the potential
mechanisms involved and be translated in the future into clinical recommendations for
the management of HIV, drug addiction and gut health to ultimately ameliorate the
continuous immune activation and inflammation observed in PLWH.
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CHAPTER III: ASSOCIATIONS BETWEEN MICROBIAL TRANSLOCATION,
IMMUNE ACTIVATION AND VITAMIN D STATUS IN DRUG USERS LIVING
WITH HIV
Abstract
Background. The human immunodeficiency virus (HIV) promotes Microbial
Translocation (MT), affects the integrity of gastrointestinal mucosa and induces immune
activation even with effective Antiretroviral Therapy (ART) use. Cocaine use may
accelerate these processes in People Living with HIV (PLWH). Vitamin D plays
protective role in antimicrobial host defense and its deficiency is associated with
intestinal diseases. Vitamin D deficiency is highly prevalent among PLWH and may be
affecting immunity as well as gut integrity. The purpose of this study was to examine
associations between MT, immune activation and vitamin D status in the context of
cocaine abuse among PLWH.

Methods. Participants were selected from the ongoing Miami Adult Studies in HIV
(MASH) cohort. Cocaine use was assessed by self-report, urine screen and blood
metabolites. Blood samples were collected to assess MT levels (LPS), immune activation
levels (sCD14, sCD163 and sCD27), gut integrity damage (I-FABP) and vitamin D
status. Data on socio-demographic characteristics, anthropometrics, diet and disease
progression were collected. Descriptive statistics, independent t-test, multiple linear and
logistic regressions were conducted to analyze the data.
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Results. A total of 100 PLWH, 66 cocaine non-users and 34 cocaine users had a mean
age was 53.37±6.88 years old. Most participants were male (51%), and African
Americans (66%). All participants were on ART and had controlled viral load (<200
copies/mL). Half of the participants were considered vitamin D deficient (≤20 ng/mL)
and 32% had insufficient levels (21-29 ng/mL). Cocaine users had higher levels of MT
than non-users (P<0.001). Cocaine use was a significant predictor for both LPS
(P=0.047) and immune activation markers sCD163 and sCD27 (P=0.002 and P=0.03,
respectively). Cocaine use and vitamin D deficiency independently predicted high levels
of MT (LPS ≥ median 0.63 EU/mL) (P<0.001 and P=0.043, respectively). Cocaine users
also were 6.66 times more likely to exhibit high MT levels than non-users (OR: 6.658
95% CI: 2.429, 18.250; P<0.001)

Conclusion. Cocaine use and impairment of vitamin D status were associated with MT
and immune activation in PLWH despite ART use and viral suppression. Therefore, it is
imperative to develop effective interventions that target lifestyle modifications, optimal
vitamin D status and mitigation of drug abuse, to more effectively decrease MT and
ultimately reduce immune activation among PLWH.

Key words. Microbial translocation, immune activation, cocaine, vitamin D
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Introduction
People Living with HIV (PLWH) exhibit pathological processes that affect the
Gastrointestinal Tract (GI). One of the main features of the HIV in the GI tract is massive
destruction of the intestinal CD4+ T cell.1,2 Studies have shown that CD4+ T cells in the
GI tract are 10-fold more frequently infected by HIV than are the cells in the blood,
suggesting that the GI tract is one of the biggest HIV targets and reservoir in the human
body.3–7 The loss and poor reconstitution of CD4+ T cells in the GI tract promote
disruption of intestinal homeostasis, mucosal regeneration and gut integrity despite
Antiretroviral Therapy (ART).7–11
Studies have demonstrated that the microbiome diversity appears to be reduced in
HIV infection.12–15 It is not surprising that the combination of reduced intestinal CD4+ T
cells and alterations in the microbiome lead to Microbial Translocation (MT) in PLWH.
Translocation of bacteria is defined as the passage or transport of the microflora or its
products from the GI tract into the systemic circulation without causing bacteremia.16,17
Several lines of evidence have confirmed that PLWH present products of MT,
specifically Lipopolysaccharide (LPS), in the circulation inducing immune activation,
which is considered a hallmark in predicting clinical outcomes of HIV infection.18–22
Immune activation has been identified as one of the factors that increase morbidity and
mortality among PLWH regardless viral suppression and ART use.
Constant low levels of virus replication from reservoirs, particularly in the GI
tract, are kept despite ART use, and it exponentially enhances immune activation in HIV
infection.21 This creates a vicious cycle where gut barrier immunity is compromised by
the HIV promoting MT and immune activation, and ultimately disease progression.
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Epidemiological studies have demonstrated that active illicit drug use, particularly
cocaine, is associated with poor adherence to ART, reduced virologic and immunologic
control, HIV disease progression and mortality.23–25 Cocaine abuse pose deleterious
effects for GI tract including weight loss, malnutrition, anorexia, reduced blood supply to
enterocytes and dysbiosis of microbiome among PLWH.26–28 In Miami, cocaine seems to
be one of the illicit drugs of choice among PLWH. In a study analyzing the illicit drug
use among PLWH in 8 U.S. cities, it was found that 40% of participants had heavy
alcohol consumption or crack-cocaine use in the preceding 12 months.29 Cocaine users
frequently mix the drug with alcohol to enhance and prolong its effect.30
Vitamin D deficiency is also highly prevalent among PLWH; the prevalence rate
ranges between 70-85%.31,32 PLWH present similar risk factors for vitamin D deficiency
as the general population including: gender (females have higher risk), limited sunlight
exposure, black ethnicity, advanced age, poor dietary vitamin D intake, obesity,
cardiovascular and renal disorders, diabetes mellitus, metabolic, hepatic steatosis, and
alcohol consumption.31,33–37 However, PLWH have additional risk factors for vitamin D
deficiency due to action of HIV itself33 and ART.38 It has been well established that HIV
promotes chronic inflammation and massive immune activation,39,40 and individuals with
vitamin D deficiency show an increase in pro-inflammatory cytokines, such as IL-6 and
TNF-a,41 and monocyte activation, which are considered key elements for HIV disease
progression.
Several studies have tried to elucidate the relationship between vitamin D
deficiency and MT among PLWH. A study found that optimal vitamin D levels were
associated with low levels of MT and inflammation PLWH.42 However, another study did
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not find significant associations between vitamin D status and MT among PLWH.43
Contradictions in the literature may be due to methodological differences. However, the
interplay between cocaine use, MT, immune activation and vitamin D status has not been
investigated. The purpose of this study is to examine the associations between MT,
immune activation and vitamin D status in the context of cocaine abuse among PLWH.
Methods
Study Participants. Participants for this cross-sectional study were selected from the
ongoing Miami Adult Studies in HIV (MASH) cohort. The MASH cohort is a
longitudinal study examining the impact of substance abuse on HIV infection, HIV/HCV
co-infection, and comorbidities with a focus on liver disease. The MASH cohort in
Miami is unique, because it has a large number of non-Hispanic Blacks, Hispanics,
women, and non-injector drug users, with predominantly heterosexual HIV- transmission
etiology. The Inclusion Criteria for this study were to be HIV mono-infected adults, age
21 and older, having undetectable HIV viral load <200 copies/ml, CD4+ T cell count
>200 cells/µl, and compliant with ART use (95%) and clinic visits for at least 6 months.
Participants were also positive for cocaine use by questionnaire, blood metabolites and/or
urine drug screen. The Exclusion Criteria included co-infection with hepatitis B or C,
detectable HIV viral load, CD4+ T cell count<200 cells/µl, diagnosis of inflammatory
bowel disease, pregnancy, hazardous alcohol use (AUDIT score >8) and current vitamin
D supplementation. After applying these criteria, a total of 100 participants were eligible
for this study.
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Laboratory analyses. Plasma samples were collected at the baseline visit and used to
assess LPS for MT, sCD14, sCD163, sCD27 for immune activation, and vitamin D
levels. LPS was measured using the Pierce Chromogenic Endotoxin Quant Kit by
Thermo Fisher Scientific (Rockford, IL, USA) according to manufacturer’s instructions
with the following modifications: samples were diluted 1:10 with endotoxin-free water to
avoid interference with background color and preheated to 70°C for 15 minutes prior to
analyses to inactivate plasma proteins. Triplicates were assessed for each sample.
Immune activation markers were measured by using the analyte-specific bead-based
Luminex multiplex immunoassays (EMD, Millipore Corporation). I-FABP, a measure of
gut integrity damage, was assessed using the Human FABP2/I-FABP Immunoassay by
R&D Systems (Minneapolis, MN, US) according to manufacturer’s instructions with a
sample dilution of 1:5. Quantification of 25(OH)D levels were measured in 25µl of
sample by the 25-Hydroxy Vitamin Ds Enzyme Immunoassay by Immunodiagnostic
Systems Ltd (Bolton, UK) according to manufacturer’s instructions. According to the
Endocrine Society Clinical Practice Guidelines, adequate levels of vitamin D in adults are
considered to be >30ng/mL (75nmol/L), insufficient levels 21-29 ng/mL (52.5-72.5
nmol/L) and deficient levels at <20 ng/mL (50nmol/L).44 For all assays, the coefficient of
variation or CV% was calculated and CV’s greater than 10% were reanalyzed.

Substance use. Cocaine use was assessed by self-report (use in the past 30 days)
questionnaire, blood metabolite and urine drug screen (American Bio Medical®).
Alcohol use was evaluated by the Alcohol Use Disorders Identification Test (AUDIT).
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Anthropometric Assessments and Dietary Intake Data. Standing height (meters), weight
(kg) and Body Mass Index (kg/m2) were assessed from parent study. Dietary intake data
were assessed by one 24-hour recall. Food models and portion size prompts were used.
Dietary intake data were analyzed using a software program (NutriBase 9 Cybersoft).
Disease Progression and Medication History. Markers of disease progression (CD4+ T
cell count and HIV viral load) were collected from the patient’s medical chart, with
participant written authorization.

Statistical Analyses
Descriptive statistics including mean, standard deviation, median, interquartile
range, standard error and percentages were used to describe the data. Independent T-test
and Mann-Whitney test were conducted to compare mean differences between cocaine
users and non-users. Variables including HIV viral load, CD4+ T cell count, sCD14,
sCD163 and sCD27 did not exhibit a normal distribution, therefore, they were log
transformed. Pearson correlation was implemented to evaluate association among
biomarkers of MT and immune activation. Multiple linear regression models were
implemented to analyze associations between MT, immune activation, vitamin D status
and cocaine use. The linear multivariable regression analysis also included a measure to
check for multicollinearity known as variance inflation factor (VIF). All models had a
VIF <5, therefore, multicollinearity was ruled out. Analyses were adjusted for potential
confounding factors including age, gender, CD4+ T count, HIV viral load, obesity,
seasonality of sunlight exposure (spring, summer, fall and winter). Logistic regression
models included dependent MT marker at the following cut-offs: LPS ≤ or ≥ median. An
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alpha less than 0.05 was considered significant. All statistical analyses were performed
using SPSS version 23.
Results
Participant Characteristics
A total of 100 PLWH were selected for this study. The non-cocaine group had a
greater proportion of participants (66%, n=66), than cocaine users (34%, n=34). For the
two groups, mean age was 53.37±6.88 years old. Cocaine users were older than nonusers, however, this difference was not statistically significant (P=0.338). Most
participants were male (51%), and African American (66%). Participants had a mean
duration of known HIV diagnosis of 17.21±7.28 years. All participants were on ART
and had controlled viral load (<200 copies/mL) with a median of 48.5 (Interquartile
Range IQR: 20-307) copies/ml. Cocaine users had higher AUDIT score than non-users
(3.12±2.50 vs. 2.03±1.96 respectively, P=0.031), indicating greater alcohol use. Among
all participants, 19% used marijuana, 11% used opioids, 1% used heroin and 2% used
fentanyl (data not shown). Participants had a mean BMI of 28.70±5.76 kg/m2 which
classify them as overweight and obesity was found in 37% of participants.
Regarding vitamin D status, 50% of participants were considered deficient (≤20
ng/ml), 32% insufficient (21-29 ng/ml) and 18% sufficient (>30 ng/ml). There were not
differences between cocaine users and non-users in terms of vitamin D deficiency or
insufficiency. Most of the samples were collected during winter (47%) and fall (27%)
seasons. Cocaine users had higher levels of MT than non-users (0.72±0.12 vs. 0.53±0.24
respectively, P<0.001). Also, cocaine users had higher levels of sCD14, sCD163, sCD27,
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however, these differences did not reach statistical significance. Cocaine users had higher
levels of I-FABP than non-users (2866.97±798.06 vs. 2337.56±1072.95, P=0.014)
indicating greater intestinal damage. Mean of vitamin D levels did not differ between
groups (Table 1).
Correlations
A Pearson product-moment correlation was run to determine the linear
relationship between continuous variables. There was a positive correlation between BMI
and CD4 + T cell count (r = 0.201, P =0.046), BMI and sCD14 levels (r =0.220,
P=0.035), I-FABP and sCD27 levels (r = 0.213, P=0.048), sCD14 and sCD163 levels (r=
0.216, P=0.038), sCD14 and sCD27 levels (r = 0.344, P=0.001). There was a negative
correlation between BMI and age (r = -0.231, P =0.021), a trend was observed for IFABP levels and BMI (r = -0.198, P =0.05) and, vitamin D and I-FABP levels (r = 0.198, P=0.05).
Association between Cocaine use and Microbial Translocation
Multiple regression analysis was carried out to investigate whether cocaine use,
age, gender, CD4+ T cell count, HIV viral load, BMI and gut integrity damage were
associated with MT levels. The results of the regression analysis indicated that the model
explained 65.3% of the variation and that the model was significant with F (7,13) =
3.501, P =0.025. Cocaine use was significantly associated with LPS levels (β=0.196; 95%
CI= 0.003, 0.390; P=0.047). In addition, gender (male) (β=-0.313; 95% CI= -0.552, 0.075; P=0.014) and lower log transformed CD4+ T cell count (β=-0.359; 95% CI= -
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0.637, -0.081; P=0.021) were significantly associated with LPS levels after controlling
for age, log HIV viral load, BMI and gut integrity (Table 3).
Table 4 showed that among cocaine users, 73.5% exhibited LPS levels ≥ median
0.63 EU/mL. Also, having LPS levels ≥ median 0.63 EU/mL were significantly
associated with gut integrity damage (P=0.02). None of the parameters for vitamin D
levels, BMI and HIV disease progression were significantly associated with median
levels of LPS.
Logistic regression analysis indicated that cocaine use and vitamin D deficiency
were significantly associated with LPS ≥ median 0.63 (IQR:0.48-0.73) EU/mL (P<0.001
and P=0.043, respectively) after controlling for age, gender, obesity and winter season.
The model correctly classified 68% of cases. In addition, cocaine users had 6.66 times
higher odds to exhibit LPS levels above the median than non-users (OR: 6.658 95% CI:
2.429, 18.250; P<0.001). In addition, vitamin D deficient participants had 2.58 times
higher odds to exhibit LPS levels ≥ median 0.63 EU/mL than participants with sufficient
levels (OR: 2.58, 95% CI: 1.032, 6.470; P=0.043) (Table 5).
Association between Cocaine use and Immune activation
A multiple regression was conducted to investigate whether cocaine use, age,
gender, CD4+ T cell count, HIV viral load, MT and gut integrity damage were associated
with immune activation. The results of the regression analysis indicated that the model
explained 82.6% of the variation and that the model was significant with F (7,11) =
7.441, P=0.002. Cocaine use was significantly associated with sCD163 levels (β=0.873;
95% CI= 0.399, 1.347; P=0.002). Age, gender (male) and lower CD4+ T cell count were
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significantly associated with sCD163 levels (β=-0.056; 95% CI= -0.094, -0.018; P=0.038,
β=-0.645; 95% CI= -1.221, -0.069; P=0.031 and β=-1.238; 95% CI= -1.937, -0.538;
P=0.002, respectively). In addition, levels of LPS and I-FABP were significantly
associated with sCD163 levels (β=1.352; 95% CI= 0.890, 1.937; P<0.001 and β=0.697;
95% CI= 0.218, 1.175; P=0.008, respectively) (Table 6). For 1-unit increase in LPS
levels there was a 1.352 increase in sCD163 levels, indicating that MT promotes immune
activation in our participants.
An additional multiple regression was carried out to investigate whether cocaine
use, age, gender, CD4+ T cell count, HIV viral load, MT and gut integrity were
associated with another biomarker of immune activation (sCD27). The results of the
regression analysis indicated that the model explained 71.1% of the variation and that the
model was significant with F (7,10) = 3.507, P =0.036. Cocaine use was significantly
associated with sCD27 levels (β=0.477; 95% CI= 0.056, 0.899; P=0.030). Gender (male)
and lower CD4+ T cell count were significantly associated with sCD27 levels (β=-0.819;
95% CI= -1.398, -0.241; P=0.010 and β=-0.002; 95% CI= -0.003, -0.001; P=0.007,
respectively). In addition, levels of LPS levels were significantly associated with sCD27
levels (β=0.716; 95% CI= 0.302, 1.131; P=0.003) after controlling for age, gender, and
HIV viral load (Table 7).
For 1-unit increase in LPS levels there was a 0.716 increase in sCD27 levels,
indicating that MT promotes immune activation in our participants. No significant
association was found between cocaine use, LPS and sCD14 levels.
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Associations among Microbial Translocation, Immune activation, Cocaine use and
Vitamin D status
Vitamin D deficiency
In participants who exhibited vitamin D deficiency, those who used cocaine
(n=15) had higher levels of MT than those who did not use cocaine (t=-2.412 df=47
P=0.02). No statistical differences were found for the immune activation markers.
A multiple regression was conducted to investigate whether cocaine use, age,
gender, obesity, winter season and smoking may significantly predict MT levels in
vitamin D deficient participants. The results of the regression analysis indicated that the
model explained 43% of the variation and that the model was significant with F (6,42) =
2.414, P =0.043. Cocaine use was significantly associated with LPS levels (β=0.162; 95%
CI= 0.005, 0.318; P=0.043) in vitamin D deficient participants. In addition, gender (male)
was significantly associated with LPS levels (β=-0.177; 95% CI= -0.315, -0.039,
P=0.013) after controlling for age, obesity, seasonality (winter) and smoking (Table 8).

Vitamin D insufficiency
In participants who had vitamin D insufficiency, Mann Whitney test revealed that
those who used cocaine (n=11) had higher levels of MT than participants who did not use
cocaine (P=0.022). No statistical differences were found for the immune activation
markers. A multiple regression was carried out to investigate whether cocaine use, age,
gender, obesity, winter season and smoking could significantly predict MT levels in
vitamin D insufficient participants. The results of the regression analysis indicated that
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the model explained 38.6% of the variation and that the model showed a trend towards
significance with F (6,23) = 2.414, P =0.05. Cocaine use was the only significant
predictor for LPS levels (β=0.234; 95% CI= 0.068, 0.399; P=0.008) among vitamin D
insufficient participants after controlling for age, obesity, winter season and smoking
(Table 9).

Dietary Intake Characteristics in Study Participants
Table 10 describes the dietary intake characteristics of participants. The 2015-2020
USDA Dietary Guideline Recommendations for Americans45 were implemented to
compare total fat % of caloric intake (20-35% caloric intake), cholesterol (<300 mg/d),
fiber (25.2-30.8g/d) and vitamin D intake (600 IU/d). We calculated the proportion of
participants exceeding these recommendations. All participants exceeded
recommendations for cholesterol intake (331.90 ± 317.43 mg/d) but no differences were
observed between cocaine and non-cocaine users (P=0.887). For total fat % calories (2035%) 46% participants exceeded recommendation, indicating that a pattern for a high fat
diet was reported. All participants had inadequate intake for dietary fiber (14.66±11.99
gr/d) and vitamin D (18.55±35.18 IU/d) but no differences were observed between
cocaine and non-cocaine users (P=0.458 and P=0.723, respectively). Interestingly, a great
proportion of participants (67%) did not consume vitamin D as reported in the 24-hour
recall.
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Discussion
We examined associations between MT, immune activation and vitamin D status
in the context of cocaine abuse among PLWH. Cocaine users had higher levels of MT
and I-FABP than non-users. We also demonstrated that cocaine was a significant
predictor for MT levels even after controlling for age, gender, HIV viral load, CD4+ T
cell count, BMI and compromised gut integrity. However, this effect was not seen for
markers of immune activation (sCD14, sCD163 and sCD27) and vitamin D levels. Our
findings contradict the only study published so far investigating the effects of cocaine on
microbiome and MT in PLWH.28 This may be due to methodological differences in
Volpe et al.28 study, since they had a smaller sample size (n=32), large proportion of
males (26/32), duration of ART use was not evaluated and cocaine use was self-reported,
which could affect the ability of the study design to detect any difference in terms of
MT.28
In addition, we showed that lower CD4+ T cell count was a significant predictor
for MT which support the premise of the deleterious effects of HIV on the GI immune
system.46,47 It is important to mention that all our participants were on stable ART and
controlled viral load (<200 copies/mL) which indicates that HIV continues to damage the
GI tract even when it is controlled in blood, promoting MT, probably due to poor CD4+
T cell control and reconstitution in the intestine.7,10,11,21
Most of the cocaine users (73.5%) had high levels of MT [LPS ≥median of 0.63
(IQR:0.48-0.73) EU/mL]. Participants that had higher levels of MT also had higher levels
of gut integrity damage when compared to those low levels of MT (2874.94±1334.18 vs.
2320.12±953.29 pg/mL, P=0.020) supporting previous findings about the role of gut
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integrity damage and MT on HIV/SIV infections of humans and rhesus macaques.48
During HIV infection, there is a massive loss of CD4+ T cells in the GI lamina propia.
This loss also affects a subtype of CD4+ T cells called T helper 17 (Th17) in the
intestine, which are responsible for the intestinal homeostasis, mucosal regeneration and
integrity,8,9 creating an environment for damage of gut integrity, increased intestinal
permeability and, consequently, MT.
A novel finding from this study was that cocaine users were 6.66 times more
likely to exhibit high MT levels than non-users, which indicates the damaging effect of
cocaine in the GI mucosa, promoting intestinal inflammation and ultimately high levels
of MT. The exact mechanism behind the impact of cocaine use in the intestine has not
been completely elucidated. However, past studies have suggested that cocaine has the
ability to dysregulate the expression of the tight junction proteins in the intestinal
epithelium promoting damage on gut integrity and hyperpermeability, which generates
gut inflammation due to the release of pro-inflammatory cytokines (IL-18 and IL-1b).49,50
Our analyses demonstrated that cocaine, MT levels, damaged gut integrity and
lower CD4 T cell count drive immune activation, marked by higher levels of sCD163 and
sCD27, indicating that cocaine use and HIV seemed to compromise gut integrity,
promote MT and, therefore, immune activation despite ART use and viral suppression.
To the best of our knowledge, this is the first study demonstrating these associations.
Regarding vitamin D status, half of our participants were vitamin D deficient and
one third were insufficient. These prevalence rates are comparable to the ones reported by
other cohort studies showing a high prevalence of vitamin D deficiency in PLWH in the
US.35,51
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Our cohort is comprised of a high proportion of African Americans and
Hispanics and almost half were obese, which represents a risk factors for vitamin D
deficiency.31
We demonstrated that in participants with impaired vitamin D status, those who
used cocaine had higher MT levels than non-users and that cocaine use was a significant
predictor for MT levels but not for immune activation, which suggest that even with
significant MT, the immune response is compromised in this population. To the best of
our knowledge, this is the first study showing that cocaine use is associated with MT
when vitamin D status is impaired.
Also, we showed that individuals that had vitamin D deficiency were 2.58 times
more likely to exhibit high MT levels than participants who did not have deficiency. Our
finding is supported by Garcia-Alvarez et al.42 in which lower levels of MT were
associated with sufficient levels of vitamin D in PLWH.42 On the other hand, our data
conflict with results showed by Missailidis et al.43 in which no association was found
between vitamin D deficiency and MT or immune activation in PLWH.43 This conflict
may be due to differences in methodology, including a small proportion of participants
with vitamin D deficiency (9%), vitamin D insufficiency was not considered, 25% of
participants were taking vitamin D supplements (400 to 1400 IU/day), and sociodemographic characteristics of study participants, as this study was conducted in
Sweden.43 In our study, 50% of participants had vitamin D deficiency and were mostly
African Americans.
Our dietary data demonstrated that PLWH seemed to follow a dietary pattern
characterized by a high fat, high cholesterol and low fiber diet. These findings support
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previous studies showing that PLWH had an increase of total fat, saturated fat and
cholesterol and low fiber intake,52–55 posing a risk for the development of chronic
conditions, including cardiovascular disease, obesity and inflammation. Our participants
had inadequate vitamin D intake and a great proportion of them did not consume vitamin
D at all. This may explain, in part, why half of our participants were vitamin D deficient.
Our findings suggest that personalized dietary interventions that focus on healthy eating
and physical activity may be beneficial in the management of HIV.
Our study had some limitations. The cross-sectional design does not allow us to
establish causation. Immune activation markers were available for only 85 study
participants. Dietary intake data were assessed by one 24-hour recall. The analysis of a
24-hour food recall was limited by important factors such as the interviewee’s memory,
concepts of food portion size, and current versus historical food consumption.
The results of this study need to be interpreted with caution due to the specific
geographical, socioeconomic and ethnical composition of study participants, as this study
included mostly minorities living in poverty, but on stable ART and controlled viral load.
However, this study provides important clinical evidence that supports the development
of strategies to ameliorate cocaine use and vitamin D deficiency among PLWH.
Conclusion
Cocaine abuse and vitamin D deficiency are relevant issues among PLWH. Our
data suggested that cocaine abuse and impaired vitamin D status are associated with MT
and immune activation in PLWH despite ART use and viral suppression. Therefore, there
is a critical need to develop effective interventions that target lifestyle modifications,
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optimal nutrition and counseling on drug abuse, to more effectively decrease MT and
ultimately immune activation among PLWH.
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Table 1. Participants Characteristics
Characteristics

Total
(n=100)

Cocaine Nonusers (n=66)

Cocaine Users
(n=34)

P value

53.37±6.88

52.89±7.38

54.29±5.77

0.338

Gender (male)

51(51)

35 (35)

16 (16)

0.674

Race/Ethnicity
African American
Hispanic
White
Other

66 (66)
29 (29)
28 (28)
6 (6)

38 (38)
23 (23)
24 (24)
4 (4)

28 (28)
6 (6)
4 (4)
2 (2)

0.011
0.103
0.100
0.603

CD4+ T (cells/μL)

630.08±344.07

628.80±298.12

632.64±426.63

0.963

HIV VL (copies/mL)

48.50 (20-307)

59 (31.5-140.25)

40 (26.5-136)

0.497

17.21±7.28

18.01±7.23

15.64±7.14

0.150

AUDIT score

2.4±2.19

2.03±1.96

3.12±2.50

0.031

Smoking (yes)

47 (47)

24 (24)

23 (23)

0.300

28.70±5.76

28.89±5.82

28.33±5.71

0.648

37 (37)

24 (24)

13 (13)

0.511

0.59±0.23

0.53±0.24

0.72±0.12

<0.001

sCD14 (pg/mL)

1038.47±424.2

1021.81±402.55

1080.73±480.7

0.552

sCD27 (pg/mL)

7.95±2.94

7.70±2.52

8.58±3.81

0.291

sCD163 (pg/mL)

635.71±418.52

613.25±431.73

692.74±385.01

0.393

2515.83± 1072.95

2337.56±1072.95

2866.97±798.06

0.014

20.97 (16.96-27.84)

19.80 (16.6826.60)

23.07 (19.2329.59)

0.087

Vitamin D Status
Deficient ≤20 ng/mL
Insufficient 21-29 ng/mL
Sufficient ³30 ng/mL

50 (50)
32 (32)
18 (18)

35 (35)
21 (21)
10 (10)

15 (15)
11 (11)
8 (8)

0.527
1.000
0.411

Seasonality
Winter
Fall
Spring
Summer

43 (43)
27 (27)
22 (22)
8 (8)

30 (30)
18 (18)
14 (14)
4 (4)

13 (13)
9 (9)
8 (8)
4 (4)

0.529
1.000
0.803
0.439

Age, years

Duration known HIV (years)

BMI (kg/m2)
Obesity (BMI>30kg/m2)
LPS (EU/mL)

I-FABP pg/mL
Vitamin D ng/mL

Bold indicates statistical significance at P<0.05. Data for continuous variables are summarized as mean ± standard deviation and
median (interquartile range IQR) with statistical comparison using T test and Mann-Whitney. Categorical variables are summarized as
count n (%) to test for proportion using Chi square. HIV VL: HIV Viral Load; BMI: body mass index; LPS: Lipopolysaccharide;
sCD14: soluble CD14; sCD27: soluble CD27; sCD163: soluble CD163; I-FABP: Intestinal Fatty Acid Binding Protein.
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Table 2. Pearson Correlation Coefficients
Variable
Age CD4+ BMI
I-FABP
Age
1
CD4+
-.09
1
BMI
-.23*
.20*
1
I-FABP
.06
-.01
-.19*
1
LPS
-.06
.06
-.17
.14
sCD14
.01
-.08
.22*
-.03
sCD163
-.11
-.03
.19
-.00
sCD27
.18
-.15
-.10
.21*
Vit. D
.13
.02
.04
-.19*

LPS

sCD14

sCD163

1
-.01
-.08
-.17
-.05

1
.21*
.34*
.06

1
.41*
.05

sCD27

1
.15

Vit. D

1

*Correlation is significant at the 0.05 level (2-tailed).

Table 3. Multiple Linear Regression Analysis Predicting Association Between Cocaine Use And Microbial
Translocation
Variable
β
SE
95% CI
P-value
Age
-0.012 0.008
-0.029, 0.006 0.170
Gender (male)
-0.313 0.111
-0.552, -0.075 0.014
Log transformed CD4+ T cell count (cells/μL)
-0.359 0.129
-0.637, -0.081 0.015
Log transformed HIV viral load (copies/mL)
0.076
0.056
-0.044, 0.197 0.193
BMI (kg/m2)
-0.015 0.007
-0.029, 0.002 0.059
Cocaine use (yes)
0.196
0.089
0.003, 0.390
0.047
Log transformed I-FABP (pg/mL)
0.171
0.103
-0.053, 0.394 0.123
Bold indicates statistical significance at P<0.05

Table 4. Differences Between Median Groups Of Lps And Cocaine Use, Gut Integrity And Vitamin D
Levels
Variable
LPS ≤0.63 (EU/mL)
P-value
LPS ³0.63 (EU/mL)
Cocaine use (yes) (%)
26.5
73.5
<0.001
I-FABP (pg/mL)
2320.125 ± 953.293
2874.947±1334.180
0.020
Vitamin D (ng/mL)
24.320 ± 7.907
22.256 ± 8.190
0.205
BMI (kg/m2)
29.290 ± 5.518
28.091 ± 5.990
0.300
CD4+ T cell count (cells/μL)
609.330±325.752
652.130± 364.678
0.540
HIV viral load (copies/mL)
83.630±74.578
81.43± 82.090
0.950
Bold indicates statistical significance at P<0.05

Table 5. Logistic Regression Analyses Predicting the Likelihood of High Microbial Translocation (LPS ≥
0.63 EU/mL) in Study Participants
Variable
β
SE
OR
95% CI OR
P-value
Age
-0.037
0.034
1.180
0.277, 0.963
0.277
Gender (male)
-0.104
0.475
0.902
0.356, 2.286
0.496
Cocaine (yes)
1.896
0.514
6.658
2.429, 18.250
<0.001
Obesity
-0.088
0.521
0.915
0.330, 2.541
0.865
Vitamin D deficiency
0.949
0.468
2.584
1.032, 6.470
0.043
Season Winter
0.513
0.465
1.670
0.671, 4.154
0.713
Bold indicates statistical significance at P<0.05
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Table 6. Multiple Linear Regression Analysis of The Effect of Cocaine Use and Microbial Translocation on
Immune Activation (Log Transformed sCD163)
Variable
β
SE
95% CI
P-value
Age
-0.056 0.017
-0.094, -0.018
0.008
Gender (male)
-0.645 0.262
-1.221, -0.069
0.031
Log transformed CD4+ T cell count (cells/μL) -1.238 0.318
-1.937, -0.538
0.002
Log transformed HIV viral load (copies/mL)
0.011
0.147
-0.313, 0.336
0.940
Cocaine use (yes)
0.873
0.215
0.399, 1.347
0.002
Log transformed LPS (EU/mL)
1.352
0.210
0.890, 1.815
<0.001
Log transformed I-FABP (pg/mL)
0.697
0.217
0.218, 1.175
0.008
Bold indicates statistical significance at P<0.05

Table 7. Multiple Linear Regression Analysis on The Effect of Cocaine Use and Microbial Translocation
on Immune Activation (Log Transformed sCD27)
Variable
β
SE
95% CI
P-value
Age
-0.019 0.017
-0.057, 0.019
0.289
Gender (male)
-0.819 0.260
-1.398, -0.241
0.010
CD4+ T cell count (cells/μL)
-0.002 0.001
-0.003, -0.001
0.007
HIV viral load (copies/mL)
-0.001 0.002
-0.005, 0.003
0.725
Cocaine use (yes)
0.477
0.189
0.056, 0.899
0.030
Log transformed LPS (EU/mL)
0.716
0.186
0.302, 1.131
0.003
Log transformed I-FABP (pg/mL)
0.399
0.199
-0.044, 0.843
0.073
Bold indicates statistical significance at P<0.05

Table 8. Multiple Linear Regression Analysis Predicting Association Between Cocaine Use and Microbial
Translocation in Vitamin D Deficient Participants
Variable
β
SE
95% CI
P-value
Age
-0.002 0.005
-0.011, 0.007
0.656
Gender (male)
-0.177 0.068
-0.315, -0.039
0.013
Cocaine use (yes)
0.162
0.078
0.005, 0.318
0.043
Obesity (BMI>30kg/m2)
-0.045 0.072
-0.190, 0.101
0.541
Season Winter
0.070
0.068
-.067, 0.207
0.307
Smoking (yes)
0.032
0.073
-0.114, 0.179
0.658
Bold indicates statistical significance at P<0.05

Table 9. Multiple Linear Regression Analysis of The Effect of Cocaine Use and Microbial Translocation in
Vitamin D Insufficient Participants
Variable
β
SE
95% CI
P-value
Age
-0.011 0.006
-0.022, 0.001
0.072
Gender (male)
-0.140 0.080
-0.306, 0.026
0.093
Cocaine use (yes)
0.234
0.080
0.068, 0.399
0.008
Obesity (BMI>30kg/m2)
-0.122 0.093
-314, 0.07
0.202
Season Winter
0.068
0.073
-0.083, 0.220
0.362
Smoking (yes)
-0.100 0.082
-0.270, 0.070
0.236
Bold indicates statistical significance at P<0.05
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Table 10. Dietary Intake Characteristics
Nutrient
Recommended
Total
Range*
(n=100)
Calories (cal)
1800-2200
1991.2±1233.3
Protein (gr)
46-56
88.4±96.4
Carbohydrate (gr)
130
242.5±172.3
Total Fat (gr)
75.9±51.0
Total Fat intake
20-35
46
35%**
Cholesterol (mg)
300
341.9±317.4
Dietary Fiber (gr)
25.2-30.8
14.6±11.9
Vitamin D (IU)
600
18.5±35.1
Inadequate
67 (67)
Vitamin D
intake***

Cocaine nonusers (n=66)
2017.8±1191.7
92.43±112.18
248.83±175.93
74.8±46.1
60.9

Cocaine users
(n=34)
1937.8±1329.9
80.39±53.15
230.06±166.90
78.1±60.4
39.1

P-value

338.9±343.1
15.0±11.9
19.4±36.2
44 (44)

347.8±263.46
13.3±12.1
16.8±33.3
23 (23)

0.887
0.458
0.723
0.473

0.763
0.470
0.612
0.783
0.142

* Recommended ranges based on adults who consume 1800-2200 kcals daily. Variations exits by age, sex and activity level.
**Participants with high fat diet (>35% Calories from Total Fat Intake)
***Participants with inadequate Vitamin D intake (0 IU/day)
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CHAPTER IV: MICROBIAL TRANSLOCATION, COCAINE USE AND OBESITY
ARE ASSOCIATED WITH INFLAMMATION AMONG DRUG USERS LIVING
WITH HIV
Abstract
Background. HIV is considered a chronic inflammatory disease. Immune activation and
inflammation persist even after long-term ART exposure and sustained viral suppression.
Cocaine abuse facilitates inflammation and disease progression in People Living with
HIV (PLWH). Persistent systemic inflammation has been associated with impaired
vitamin D status among PLWH. The purpose of this study was to examine associations
between inflammation and vitamin D status in the context of cocaine abuse among
PLWH.
Methods. One hundred cocaine users and non-users living with HIV were selected from
the ongoing Miami Adult Studies in HIV (MASH) cohort. Cocaine use was assessed by
self-report, urine screen and blood metabolites. Blood samples were collected to assess
markers of inflammation (hs-CRP, IL-6 and TNF-α), immune activation (sCD14 and
sCD163), microbial translocation (LPS), and vitamin D status. Data on sociodemographic characteristics, anthropometrics and disease progression were collected by
the MASH cohort. Descriptive statistics, independent t-test, multiple linear regression
models, and logistic regressions were conducted to analyze the data.
Results. A total of 100 participants consisted of 66 cocaine non-users and 34 cocaine
users. The mean age of the participants was 53.37±6.88 years old. Most participants were
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male (51%), and African Americans (66%). All participants were on ART and had
controlled viral load (<200 copies/mL). Half of the participants were considered vitamin
D deficient (≤20 ng/mL) and 32% insufficient (21-29 ng/mL). Overall, participants had a
mean hs-CRP levels of 3.70±3.57 mg/dL. Inflammation, defined as hs-CRP >3mg/dL
was found in 41% of all participants. LPS was a significant predictor of inflammation
(P=0.033) in all participants. In cocaine users, alcohol use was associated with higher hsCRP levels (P=0.037), and BMI was a significant predictor for inflammation (OR:1.256
95% CI: 1.013, 1.557; P=0.038). No association was found between vitamin D status and
systemic inflammation in either the cocaine users or non-users.
Conclusion. Inflammation was associated with MT, cocaine use and higher BMI among
PLWH despite ART use and viral suppression. Despite widespread vitamin D deficiency,
vitamin D status was not associated with inflammation. There is a critical need to develop
effective approaches that target drug abuse and obesity among PLWH.
Key words. Inflammation, cocaine, vitamin D, HIV
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Introduction
Immune activation is defined as a phenomenon characterized by complex
processes that stimulate and activate the immune system to generate constant
inflammation.1 During the course of HIV disease, low grade chronic inflammation
develops with continuous activation of immune cells and cytokines, which can be
stimulated for years.2 It has been suggested that during HIV infection there is an
imbalance between cytokines resulting in an overproduction of pro-inflammatory Th2
type and underproduction of Th1 type contributing to immune activation and
inflammation.3 Immune activation and inflammation persist even after long-term ART
exposure and sustained viral suppression in the GI tract, affecting the ability of the
immune system to reconstitute CD4+ T cell in this system.4–6 It has been proposed that
persistent systemic inflammation in people living with HIV (PLWH) with suppressed
viral load is associated with the damage of the gastrointestinal mucosa and microbial
translocation (MT).7,8
Several studies have shown that products of MT, specifically Lipopolysaccharide
(LPS), is present in the circulation of PLWH induce inflammation and immune
activation, and predict clinical outcomes of HIV infection.9–13 Therefore, immune
activation and inflammation has been identified as key determinants that increase
morbidity and mortality among PLWH regardless viral suppression and ART
exposure.13,14
Epidemiological studies have also demonstrated that illicit drug use, particularly
cocaine, is associated with poor adherence to ART, reduced virologic and immunologic
control, systemic inflammation, HIV disease progression and mortality.15–18 Cocaine
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reduces CD4+ T cell count and increases HIV viral load17 potentially through its action
on thymic endocrine function, preventing immune recovery.19
Vitamin D deficiency is highly prevalent among PLWH, ranging between 7085%.20,21 PLWH present similar risk factors for vitamin D deficiency as healthy, uninfected individuals, including gender (females have higher risk), limited sunlight
exposure, black ethnicity, advanced age, poor dietary vitamin D intake, obesity,
cardiovascular and renal disorders, diabetes mellitus, metabolic, hepatic steatosis, and
alcohol consumption.20,22–26 It has been well established that HIV promotes chronic
inflammation and massive immune activation,3,27 and individuals with vitamin D
deficiency show an increase in pro-inflammatory cytokines, such as IL-6 and TNF-a,28
and monocyte activation, which are considered key elements for HIV disease
progression.
Other studies have tried to elucidate the relationship between vitamin D
deficiency and inflammation among PLWH. One study found that optimal vitamin D
levels were associated with low levels of MT and inflammation among PLWH.29 In
addition, PLWH with vitamin D deficiency exhibit high levels of systemic inflammation
as measured by IL-6 and TNFα.28 However, a different study did not find significant
associations between vitamin D status and other inflammatory biomarkers including
highly sensitive C reactive protein (hs-CRP), IL-17, IL-4 and IL-10.30 Contradictions in
the literature may be due to methodological dissimilarities. However, the interplay
between cocaine use, inflammation and vitamin D status has not been adequately
investigated. The purpose of this study is to examine the associations between
inflammation and vitamin D status in the context of cocaine abuse among PLWH.
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Methods
Study Participants. Participants for this cross-sectional study were selected from the
ongoing Miami Adult Studies in HIV (MASH) cohort. The MASH cohort is a
longitudinal study investigating the impact of substance abuse on HIV and HCV
infection, HIV/HCV co-infection, and comorbidities. The MASH cohort in Miami is
unique because it has a large number of non-Hispanic Blacks, Hispanics, women, and
non-injecting drug users, with predominantly heterosexual HIV- transmission etiology.
The Inclusion Criteria for this study were to be HIV mono-infected adults, age 21 and
older, having undetectable HIV viral load <200 copies/ml, CD4+ T cell count >200
cells/µl, and compliant with ART use (95%) and clinic visits for at least 6 months.
Participants were also positive for cocaine use by questionnaire, blood metabolites and/or
urine toxicology. The Exclusion Criteria included co-infection with hepatitis B or C,
detectable HIV viral load, CD4+ T cell count<200 cells/µl, diagnosis of inflammatory
bowel disease, pregnancy, hazardous alcohol use (AUDIT score >8) and current vitamin
D supplementation. After eligibility criteria, the samples and data of the first 100
participants who were eligible for this study were utilized.

Laboratory analyses. Plasma samples were collected at the baseline visit and used to
assess inflammatory markers including IL-6, TNFα and hs-CRP, marker of MT, immune
activation (sCD14 and sCD163) and vitamin D levels. Inflammatory and immune
activation markers were measured using the analyte-specific bead-based Luminex
multiplex immunoassays (EMD, Millipore Corporation). Marker concentrations were
calculated using a standard curve derived from the known reference concentration
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supplied by the manufacturer. Concentrations obtained below the sensitivity limit of
detection (LOD) of the method were recoded to the mid-point between zero and the LOD
for that analyte for statistical comparisons. Levels of hs-CRP were assessed by
LabCorp®. Inflammation was defined as hs-CRP >3 mg/dL, based on the Centers for
Disease Control and Prevention (CDC)/American Heart Association guidelines.31
Quantification of 25(OH)D levels were measured in 25ul of sample by the 25-Hydroxy
Vitamin Ds Enzyme Immunoassay by Immunodiagnostic Systems Ltd (Bolton, UK)
according to manufacturer’s instructions. According to the Endocrine Society Clinical
Practice Guidelines, adequate levels of vitamin D in adults are considered to be
>30ng/mL (75nmol/L), insufficient levels 21-29 ng/mL (52.5-72.5 nmol/L) and deficient
levels at <20 ng/mL (50nmol/L).32 Microbial translocation marker, LPS, was measured
using the Pierce Chromogenic Endotoxin Quant Kit by Thermo Fisher Scientific
(Rockford, IL, USA) according to manufacturer’s instructions with the following
modifications: samples were diluted 1:10 with endotoxin-free water to avoid interference
with background color and preheated to 70°C for 15 minutes prior to analyses to
inactivate plasma proteins. Triplicates were assessed for each sample. For all assays, the
coefficient of variation or CV% was calculated and CV’s greater than 10% were
reanalyzed.
Substance use. Cocaine use was assessed by self-report (use in the past 30 days)
questionnaire, blood metabolites and urine drug screen (American Bio Medical®).
Alcohol use was evaluated by the Alcohol Use Disorders Identification Test (AUDIT).
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Anthropometric Assessments. Standing height (meters), weight (kg) and Body Mass
(kg/m2) Index were collected from parent study’s database.
Disease Progression and Medication History. Markers of disease progression (CD4+ T
cell count and viral load) were collected from the patient’s medical chart with the
participant’s written authorization.
Statistical Analyses
Descriptive statistics including mean, standard deviation, median, interquartile
range (IQR), standard error and percentages were used to describe the data. Independent
T-test and Mann-Whitney test were conducted to compare mean differences between
cocaine users and non-users. The variable HIV viral load and CD4+ T cell count did not
exhibit a normal distribution; therefore, it was log transformed. Cytokine (IL-6 and TNFa) concentrations were positively skewed due to high proportions of values under the
limit of detection (LOD); these were replaced with the LOD minus a decimal. Pearson
correlations were implemented to evaluate association among biomarkers of
inflammation, immune activation and HIV disease progression. Multiple linear regression
models were implemented to analyze associations between inflammation, vitamin D
status and cocaine use. The linear multivariable regression analysis also included a
measure to check for multicollinearity known as variance inflation factor (VIF). All
models had a VIF <5, therefore multicollinearity was ruled out. Analyses were adjusted
for potential confounding factors including age, gender, CD4+ T count, HIV viral load,
AUDIT score and smoking.
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Logistic regression models included dependent variable hs-CRP at the following
cut-offs: hs-CRP <3mg/dL or ≥3mg/dL. An alpha less than 0.05 was considered
significant. All statistical analyses were performed using SPSS version 23.

Results
Participant Characteristics
A total of 100 PLWH were selected for this study. The proportion of cocaine nonuser was greater (66%, n=66), than of cocaine users (34%, n=34). For the two groups,
mean age was 53.37±6.88 years old. Cocaine users were older than non-users, however,
this difference was not statistically significant (P=0.338). Most participants were male
(51%), and African American (66%). Participants had a mean duration of known HIV
diagnosis of 17.21±7.28 years. All participants were on ART and had controlled viral
load (<200 copies/mL) with a median of 48.5 (Interquartile range: 20-307) copies/mL.
Among all participants, 19% used marijuana, 11% used opioids, 1% used heroin and 2%
used fentanyl (data not shown). Cocaine users had higher AUDIT score than non-users
(3.12±2.50 vs. 2.03±1.96 respectively, P=0.031), indicating greater alcohol use.
Participants had a mean BMI of 28.70±5.76 kg/m2 which classify them as overweight;
obesity was found in 37% of participants.
In regard to vitamin D status, 50% of participants were considered deficient (≤20
ng/mL), 32% insufficient (21-29 ng/mL) and 18% sufficient (>30ng/mL). The majority
of samples were collected during winter (47%) and fall (27%) seasons. Cocaine users had
higher levels of MT than non-users (0.72±0.12 vs. 0.53±0.24, P<0.001). Also, cocaine
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users had higher levels of sCD14 and sCD163, however, these differences did not reach
statistically significant. Vitamin D levels did not differ between groups (Table 1).
Overall, participants had a mean hs-CRP levels of 3.70±3.57 mg/dL, which meets
the criteria for inflammation, defined as hs-CRP ≥ 3mg/dL. Inflammation was found in
41% of all participants. There were no statistical significance differences in terms of IL-6
and TNF-ɑ between cocaine users and non-users.

Correlations
A Pearson product-moment correlation was run to determine the linear
relationship between continuous variables. There was a positive correlation between BMI
and CD4+ T cell count (r = 0.201, P =0.046), BMI and sCD14 levels (r =0.220, P=0.035),
BMI and hs-CRP levels(r = 0.225, P=0.028), and sCD14 and TNF-α levels (r = 0.260,
P=0.019), indicating that BMI was associated with both inflammation and immune
activation. There was an inverse correlation between BMI and age (r = -0.231, P =0.021).
Vitamin D levels were not correlated with inflammatory markers.
Association among Cocaine use, Microbial Translocation and Vitamin D status with
Inflammation
A logistic regression model was conducted to evaluate associations among
cocaine use, MT and vitamin D status with inflammation (hs-CRP ≥ 3mgdL). The model
showed that LPS was a significant predictor of inflammation (P=0.033) after controlling
for age, gender, CD4+ T cell count and cocaine use. The model correctly classified
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64.6% of cases. Vitamin D deficiency did not show a significant association with
inflammation (Table 3).
Table 4 showed that participants who exhibited inflammation (hs-CRP ≥
3mg/dL) had higher BMI (P=0.045), higher IL-6 levels (P=0.049) and immune activation
as measured by sCD163 levels (P=0.024) when compared with participants who did not
exhibit inflammation (hs-CRP<3 mg/dL). In addition, there were no statistical differences
between hs-CRP groups in terms of vitamin D levels.
Association among HIV, Substance Use and Inflammation in Cocaine users living with
HIV
Multiple regression analysis was carried out to investigate whether HIV disease
progression markers and substance use predict inflammation in cocaine users. The results
of the regression indicated that the model explained 92.7% of the variation and that the
model was significant with F (6,8) = 17.940, P =0.049. Age was significantly associated
with hs-CRP levels (β=0.774; 95% CI= 0.147, 1.401; P=0.034). In addition, AUDIT
score was significantly associated with hs-CRP levels (β=1.158; 95% CI= 0.175, 2.141;
P=0.037) after controlling for gender, CD4+ T cell count, log transformed HIV viral load
and smoking. For 1-unit increase in AUDIT score, there was a 1.158 increase in hs-CRP
levels in cocaine users living with HIV (Table 5).
Logistic regression analyses indicated that BMI was significantly associated with
inflammation as measured by hs-CRP ≥ 3mg/dL in cocaine users (P=0.038) after
controlling for age, log transformed CD4+ T cell count, HIV viral load <20 copies/mL,
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and smoking. The model correctly classified 69.7% of cases. In addition, for 1-unit
increase in BMI, there was a 1.256 increase in inflammation in cocaine users [Odds Ratio
(OR): 1.256 95% CI: 1.013, 1.557; P=0.038] (Table 6). Vitamin D status, including
deficiency and insufficiency, was not associated with inflammatory markers in our
participants.
Discussion
We examined the associations between inflammation, MT and vitamin D status in
the context of cocaine abuse among PLWH. Our participants exhibited a mean hs-CRP of
3.70±3.57 mg/dL which meets criteria for inflammation, and over 40% had high levels of
inflammation. Cocaine users had higher levels of hs-CRP than non-users, however, this
difference did not reach statistical significance. Nevertheless, we observed that
inflammation was prevalent in our participants, despite ART use and viral suppression.
This is supported by other studies showing residual immune activation and inflammation
among PLWH even after the introduction of ART.4,6,33–35 Over the past decade, evidence
has shown that HIV infection is a chronic inflammatory disease that has features similar
to those of other inflammatory non-infectious conditions.36
We found that participants who exhibit inflammation (hs-CRP ≥ 3mg/dL) had
higher BMI, IL-6 and sCD163 levels when compared to those who did not exhibit
inflammation. Moreover, levels of MT were associated with inflammation in our
participants, which confirms the findings of other studies in PLWH on ART and with
undetectable viral load.37–39 It has been well established that damaged gut integrity in
HIV infection is a major driver for MT. This process allows the passage of products of
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MT, such as LPS, into systemic circulation, initiating a strong immune response and
chronic inflammation.10,12,35,40–42 Although, cocaine use was not directly associated with
inflammation in our study, we demonstrated that cocaine users had higher MT levels than
non-users (Chapter 3); this could indicate the possible role of cocaine in damaging gut
integrity, promotion of MT, and ultimately causing systemic inflammation.43,44
We further analyzed cocaine users living with HIV. We found that aging and
alcohol use were associated with hs-CRP levels. This finding corroborates previous
association of substance use, particularly alcohol and cocaine, with inflammation among
PLWH.45 Alcohol and cocaine are often used together,46 and this combination provides
an additive effect, which causes immune and neurological toxicity and dependence
severity.47
In addition, we showed that higher BMI independently predicted inflammation
(hs-CRP ≥ 3mg/dL) in cocaine users living with HIV. This is a novel finding that
indicates that cocaine use and higher BMI among PLWH provide a synergistic effect that
not only promotes systemic inflammation and HIV disease progression, but it potentiates
the risk for non-AIDS related conditions, particularly cardiovascular diseases (CVD).
Most importantly, our finding that higher BMI was associated with inflammation in
cocaine users living with HIV, and that these are 1.256 times more likely to have high
inflammation than cocaine users with lower BMI, may be of clinical relevance for the
prevention of excessive weight gain in this population. In our cohort, cocaine users living
with HIV had a mean BMI of 28.33±5.71 kg/m2, which classified most of them as
overweight and 38.2% were obese, which is comparable with the overweight and obesity
rates in the general US population.48
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It has been suggested that in the general population, cocaine use promotes high
levels of hs-CRP, promotes coronary vasoconstriction, high blood pressure which may
increase the risk for CVD events.49 Studies also showed significant association between
cocaine use and obesity with increased risk for CVD events among PLWH.50–53 This
identifies PLWH who use cocaine as a vulnerable population for sustained inflammation
caused by HIV itself,1 and weight gain, which may increase risks for CVD and other nonAIDS co-morbidities.
It is important to mention that cocaine use was not associated with other
inflammatory markers including IL-6 and TNF-ɑ. Other studies, however, have shown
that cocaine use was associated with levels of IL-6 and TNF-ɑ, which are considered
inflammatory markers.54,55 These discrepancies may be due to that in our study, we had a
high proportion of values under levels of detection for IL-6, and TNF-ɑ, and that the
inflammatory processes associated with HIV were ameliorated by controlled viral load in
our participants.
In our study, vitamin D status was not associated with inflammatory biomarkers
and the rate of vitamin D deficiency did not differ between cocaine users and non-users.
This finding supports some studies in the literature showing no association between
vitamin D status and inflammation among PLWH.30,56,57 In fact, Hoffman et al.56
demonstrated that even after vitamin D supplementation (2,000 IU for 12 weeks) in those
who were insufficient, the inflammatory biomarkers, hs-CRP and TNF-ɑ did not show a
significant improvement.56 On the other hand, different studies showed a positive
association between vitamin D status and inflammation among PLWH.28,29,58 These
studies, however, were conducted on PLWH on ART and ART-naïve, and some did not
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include individuals with controlled viral load, making direct comparisons with our study
difficult. Also, discrepancies may be due to methodological differences, including, but
not limited, to sample size, cross-sectional study design, and socio-demographic
characteristics of participants.
Our study had limitations. The cross-sectional design does not allow us to
establish causation. Our analysis of cytokines (IL-6 and TNF-a) was restricted by large
proportions of undetectable values, which may have affected findings and were only
available for 85 study participants. The results of this study need to be interpreted with
caution because of the specific geographical and ethnical characteristics of our cohort. In
addition, our population, despite living in poverty, were on stable ART and had
suppressed viral load. However, this study provides important clinical evidence that
supports the development of strategies to ameliorate cocaine abuse and obesity among
PLWH.
Conclusion
Our data showed that MT was independently associated with inflammation in
PLWH. In addition, high BMI combined with cocaine use were associated with
inflammation in PLWH despite ART use and viral suppression. Vitamin D status was not
associated with inflammation in our participants. Therefore, there is a need to develop
effective strategies focused on lifestyle modifications, including weight management and
counseling on drug abuse, to more effectively decrease systemic inflammation, and
ultimately, reduce incidence of chronic inflammatory diseases common in PLWH
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Table 1. Participant Characteristics
Characteristics

Total
(n=100)
53.37±6.88
51(51)

Cocaine Nonusers (n=66)
52.89±7.38
35 (35)

Cocaine Users
(n=34)
54.29±5.77
16 (16)

P value

Race/Ethnicity
African American
Hispanic
White
Other
CD4+ T cells/µL

66 (66)
29 (29)
28 (28)
6 (6)
630.08±344.07

38 (38)
23 (23)
24 (24)
4 (4)
628.80±298.12

28 (28)
6 (6)
4 (4)
2 (2)
632.64±426.63

0.011
0.103
0.100
0.603
0.963

HIV Viral Load copies/ml

48.50 (20-307)

59 (31.5-140.25)

40 (26.5-136)

0.497

17.21±7.28

18.01±7.23

15.64±7.14

0.150

AUDIT score

2.4±2.19

2.03±1.96

3.12±2.50

0.031

Smoking (yes)

47 (47)

24 (24)

23 (23)

0.300

28.70±5.76
37 (37)
0.59±0.23
1038.47±424.20
635.71±418.52
3.70±3.57
41 (41)
0.7 (6.6-50.8)

28.89±5.82
24 (24)
0.53±0.24
1021.81±402.55
613.25±431.73
3.59±3.64
25 (25)
24.8 (8.5-55.5)

28.33±5.71
13 (13)
0.72±0.12
1080.73±480.73
692.74±385.01
3.95±3.49
16 (16)
4.9 (3.3-28.3)

0.648
0.511
<0.001
0.552
0.393
0.638
0.251
0.453

8.02 (5.7611.44)
20.97 (16.9627.84)

8.31 (5.78-11.44)

7.48 (3.05-11.47)

0.445

19.80 (16.6826.60)

23.07 (19.2329.59)

0.087

50 (50)
32 (32)
18 (18)

35 (35)
21 (21)
10 (10)

15 (15)
11 (11)
8 (8)

0.527
1.000
0.411

43 (43)
27 (27)
22 (22)
8 (8)

30 (30)
18 (18)
14 (14)
4 (4)

13 (13)
9 (9)
8 (8)
4 (4)

0.529
1.000
0.803
0.439

Age, years
Gender (male)

Duration of known HIV (years)

2

BMI, kg/m
Obesity (BMI>30kg/m2)
LPS EU/mL
sCD14 (pg/mL)
sCD163 pg/mL
hs-CRP mg/dL
hs-CRP ≥ 3mg/dL
IL-6 pg/mL
TNF-ɑ pg/mL
Vitamin D ng/mL
Vitamin D Status
Deficient <20 ng/mL
Insufficient 21-29 ng/mL
Sufficient >30 ng/mL
Seasonality
Winter
Fall
Spring
Summer

0.338
0.361

Bold indicates statistical significance at P<0.05. Data for continuous variables are summarized as mean ± standard deviation and
median (interquartile range IQR) with statistical comparison using T test and Mann-Whitney, respectively. Categorical variables are
summarized as count n (%) to test for proportions using Chi square. BMI: body mass index; LPS: Lipopolysaccharide; sCD163:
soluble CD163; hs-CRP: highly sensitive C-reactive protein; IL-6: interleukin 6; TNF-ɑ: tumor necrosis factor- alpha.
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Table 2. Pearson Correlation Coefficients
Variable
Age
CD4+
BMI
Age
1
CD4+
-.099
1
BMI
-.231*
.201*
1
IL-6
.027
.014
.053
TNF-α
-.001
-.158
-.062
Hs-CRP
.111
.096
.225*
sCD14
.013
-.081
.220*
Vit. D
.131
.029
.043

IL-6

TNF-α

Hs-CRP

sCD14

Vit. D

1
-.109
.206
.060
-.044

1
-.142
-.260*
.142

1
.077
.021

1
.067

1

*Correlation is significant at the 0.05 level (2-tailed).

Table 3. Logistic Regression Analysis of The Effect Demographics, Cocaine Use, Microbial Translocation,
HIV And Vitamin D Status on Inflammation (Hs-CRP≥ 3 mg/dL)
Variable
β
SE
OR
95% CI OR
P-value
Age
0.015
0.032 1.015
0.952, 1.081
0.651
Gender
0.103
0.489 1.109
0.426, 2.890
0.832
Log transformed CD4+ T cell count (cells/μL) 0.483
0.489 1.621
0.621, 2.227
0.324
Cocaine (yes)
0.810
0.519 2.247
0.813, 6.211
0.119
LPS (EU/mL)
2.347
1.104 0.096
0.011, 832
0.033
Vitamin D deficiency
0.489
0.447 1.631
0.681, 3.915
0.273
Bold indicates statistical significance at P<0.05

Table 4. Differences Between Hs-CRP Groups By Cocaine Use, Immune Activation, BMI and Vitamin D
Levels
Variable
Hs-CRP <3 (mg/dL)
Hs-CRP ≥ 3 (mg/dL)
P-value
Cocaine use (yes) (%)
30.5
39
0.251
CD4+ T cell count (cells/μL)
586.53 ± 251.81
642.88 ± 392.102
0.403
HIV viral load (copies/mL)
64.89 ± 46.22
80.45 ± 73.35
0.571
BMI (kg/m2)
27.38 ± 5.02
29.64 ± 5.87
0.045
IL-6 (pg/mL)
10.59 ± 24.17
27.34 ± 47.86
0.049
sCD163 (pg/mL)
535.00 ± 355.63
726.63 ± 429.08
0.024
Vitamin D (ng/mL)
22.93 ± 7.57
23.72 ± 8.77
0.637
Bold indicates statistically significant at P<0.05

Table 5. Multiple Linear Regression Analysis of The Effect of Alcohol Consumption and Age on
Inflammation in Cocaine Users Living with HIV
Variable
β
SE
95% CI
P-value
Age
0.774
0.146
0.147, 1.401
0.034
Gender
-2.807
1.592
-9.656, 4.043
0.220
CD4+ T cell count (cells/μL)
0.007
0.002
-0.003, 0.017
0.085
Log transformed HIV viral load
1.664
0.729
-1.491, 4.778
0.153
AUDIT score
1.158
0.228
0.175, 2.141
0.037
Smoking
-0.893
1.976
-9.393,7.607
0.695
Bold indicates statistically significant at P<0.05
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Table 6. Logistic Regression Analysis of The Effect of BMI, HIV and Smoking on Inflammation (Hs-CRP
≥ 3 mg/dL) in Cocaine Users Living with HIV
Variable
β
SE
OR
95% CI OR
P-value
Age
0.119 0.081
1.126 0.961, 1.319
0.142
Log transformed CD4+ T cell count (cells/μL)
0.495 0.629
1.641 0.323, 8.329
0.550
HIV viral load <20 copies/mL
0.781 0.947
2.184 0.343, 13.913 0.408
Smoking
0.275 0.947
0.759 0.119, 4.855
0.771
2
BMI (kg/m )
0.228 0.110
1.256 1.013, 1.557
0.038
Bold indicates statistically significant at P<0.05
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CHAPTER V: GUT INTEGRITY, INTESTINAL INFLAMMATION AND VITAMIN
D STATUS IN DRUG USERS USERS LIVING WITH HIV
Abstract
Background. The gastrointestinal tract is profoundly affected by HIV, which damages the
gut, decreasing its integrity and causing intestinal inflammation regardless of
Antiretroviral Therapy (ART) use and virologic control. Cocaine abuse seems to
accelerate these processes in People Living with HIV (PLWH), who also manifest a high
prevalence of vitamin D deficiency. These factors associate with lifestyle and the disease
not only compromised immunity but also gut integrity in this population. The purpose of
this study was to evaluate associations between gut integrity damage, intestinal
inflammation and vitamin D status in the context of cocaine abuse among PLWH.
Methods. One hundred cocaine users and non-users living with HIV were selected from
the ongoing Miami Adult Studies in HIV (MASH) cohort. Cocaine use was assessed by
self-report, urine screen and blood metabolites. Blood samples were collected to assess
gut integrity damage levels (I-FABP), intestinal inflammation (IL-17 and IL-22), MT
levels (LPS), and vitamin D status. Data on socio-demographic characteristics,
anthropometrics, dietary intake and disease progression were collected. Descriptive
statistics, independent t-test, multiple linear and logistic regressions were conducted to
analyze the data.
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Results. A total of 100 participants consisted of 66 cocaine non-users and 34 cocaine users.
For the two groups, mean age was 53.37±6.88 years old. Most participants were male
(51%), and African Americans (66%). All participants were on ART and had suppressed
viral load (<200 copies/ml). Half of the participants were considered vitamin D deficient
(≤20 ng/ml) and 32% insufficient (21-29 ng/ml). Cocaine users had higher levels of IFABP than non-users (P=0.014). Cocaine use and a high fat diet were significant predictors
for high levels of damaged gut integrity [I-FABP ≥ median 2460.43 (IQR:1813.632995.61) pg/ml, P=0.043 and P=0.016 respectively] but not vitamin D status. Cocaine users
were 3.04 times more likely to exhibit high gut integrity damage than non-users (OR: 3.038
95% CI: 1.038, 8.894; P=0.043). Cocaine users with intestinal inflammation, had 3.43
times higher odds to exhibit high levels of gut integrity damage than cocaine users without
intestinal inflammation (OR: 3.43 95% CI: 1.077, 10.934; P=0.037).
Conclusion. Cocaine use and high fat diets were independently associated with gut integrity
damage and intestinal inflammation in PLWH despite ART use and viral suppression. Our
study provided preliminary data for the development of future research focusing on dietary
interventions for gut health and counseling on drug to more effectively decrease intestinal
damage, and ultimately chronic inflammation among PLWH.
Key words. Gut integrity damage, intestinal inflammation, cocaine, vitamin D
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Introduction
The intestinal barrier is considered a complex anatomical structure that separates
the internal milieu from the luminal intestine.1,2 This structure provides a physical barrier
with a cellular component for the protection and function of the intestine. Intestinal
epithelium is a key element of the intestinal barrier that plays a central role in intestinal
immunity.3–5 Preserving gut integrity is a fundamental task for the intestinal epithelium,
and it is regulated by tight junction structures, diet quality, short-chain fatty acids,
prebiotics, probiotics and the microbiome.2
The negative effects of the HIV enteropathy were highlighted by the extensive
depletion of the CD4+ T cells in the gastrointestinal (GI) tract, poor mucosal
reconstitution, physical destruction of the epithelial barrier, increased permeability and
local inflammation. These factors pose a greater risk for microbial translocation (MT),
immune activation and chronic inflammation.6–11
Studies have demonstrated that active illicit drug use, particularly cocaine, is
associated with poor adherence to ART, reduced virologic and immunologic control, HIV
disease progression and mortality.12–14 Cocaine abuse poses harmful effects for the GI
tract, including malnutrition, anorexia, reduced blood supply to enterocytes and dysbiosis
of microbiome among People Living with HIV (PLWH).15–17 Epidemiological data have
shown that prevalence of vitamin D deficiency among PLWH ranges between 7085%.18,19 In vitro studies demonstrated that vitamin D is capable of decreasing intestinal
permeability and preserve gut integrity via signaling of Vitamin D Receptors (VDR) in
the intestine.20–22
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In relation to intestinal damage, Intestinal Fatty Acid Binding Protein (I-FABP)
has been proposed as a reliable marker of gut integrity damage among PLWH. Studies
have revealed that adults living with HIV had increased I-FABP levels in the circulation
inducing MT, immune activation, and increased mortality in this population.23–30
Massive depletion of CD4+ T cells and gut integrity during HIV, promotes intestinal
inflammation affecting IL-17 and IL-22-producing cells, which are responsible for
mucosal immunity and preservation of intestinal homeostasis.6,31 However, association
between gut integrity damage, intestinal inflammation and vitamin D status in the context
of cocaine abuse has not been investigated yet. The purpose of this study was to evaluate
those association.

Methods
Study Participants. Participants for this cross-sectional study were selected from the
ongoing Miami Adult Studies in HIV (MASH) cohort. The MASH cohort is a
longitudinal study investigating the impact of substance abuse on HIV infection,
HIV/HCV co-infection, and comorbidities with a focus on liver disease. The MASH
cohort in Miami is unique because it has a large number of non-Hispanic Blacks,
Hispanics, women, and non-injector drug users, with predominantly heterosexual HIVtransmission etiology. The Inclusion Criteria for this study were to be HIV mono-infected
adults, age 21 and older, having undetectable HIV viral load <200 copies/ml, CD4+ T
cell count >200 cells/µl, and compliant with ART use (95%) and clinic visits for at least 6
months. Participants were also positive for cocaine use by questionnaire, blood
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metabolites and/or urine toxicology. The Exclusion Criteria included co-infection with
hepatitis B or C, detectable HIV viral load, CD4+ T cell count<200 cells/µl, diagnosis of
inflammatory bowel disease, pregnancy, hazardous alcohol use (AUDIT score >8) and
current vitamin D supplementation. After eligibility criteria, a total of 100 participants
were eligible for this study.
Laboratory analyses. Plasma samples were collected at the baseline visit and used to
assess I-FABP for gut integrity damage, cytokines IL-17 and IL-22 for intestinal
inflammation, LPS for MT, and vitamin D levels. I-FABP was measured using the
Human FABP2/I-FABP Immunoassay by R&D Systems (Minneapolis, MN, US)
according to manufacturer’s instructions with a sample dilution of 1:5. LPS was
measured using the Pierce Chromogenic Endotoxin Quant Kit by Thermo Fisher
Scientific (Rockford, IL, USA) according to manufacturer’s instructions with the
following modifications: samples were diluted 1:10 with endotoxin-free water to avoid
interference with background color and preheated to 70°C for 15 minutes prior to
analyses to inactivate plasma proteins. Triplicates were assessed for each sample.
Intestinal inflammation markers were measured by using the analyte-specific bead-based
Luminex multiplex immunoassays (EMD, Millipore Corporation). Quantification of
25(OH)D levels were measured in 25µl of sample by the 25-Hydroxy Vitamin Ds
Enzyme Immunoassay by Immunodiagnostic Systems Ltd (Bolton, UK) according to
manufacturer’s instructions. According to the Endocrine Society Clinical Practice
Guidelines, adequate levels of Vitamin D in adults are considered to be >30ng/mL
(75nmol/L), insufficient levels 21-29 ng/mL (52.5-72.5 nmol/L) and deficient levels at
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<20 ng/mL (50nmol/L).32 For all assays, the coefficient of variation or CV% was
calculated and CVs greater than 10% were reanalyzed.
Substance use. Cocaine use was assessed by self-report (use in the past 30 days)
questionnaire, blood metabolite and urine drug screen (American Bio Medical®).
Alcohol use was evaluated by the Alcohol Use Disorders Identification Test (AUDIT).
Anthropometric Assessments and Dietary Data. Standing height (meters), weight (kg) and
Body Mass (kg/m2) Index were assessed from the parent study datasets. Dietary intake data
were assessed by one 24-hour recall. Food models and portion size prompts were used.
Dietary intake data were analyzed in a software program (NutriBase 9 Cybersoft).
Disease Progression and Medication History. Markers of disease progression (CD4+ T
cell count and viral load) were collected from the patient’s medical chart with
participants’ written authorization.
Statistical Analyses
Descriptive statistics including mean, standard deviation, median, interquartile
range (IQR), standard error and percentages were used to describe the data. Independent
T-test was conducted to compare mean differences between cocaine users and non-users.
Variables HIV viral load and CD4+ T cell count did not exhibit a normal distribution;
therefore, it was log transformed. Our data showed that IL-17 and IL-22 levels had high
proportions of values under the limit of detection (LOD). For the purpose of these
analyses, we replaced these values with the LOD minus a decimal. In the case of IL-17,
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low values were considered at <1.99 pg/mL and for IL-22, low values were considered at
<0.01pg/mL
Pearson correlations were implemented to evaluate association among biomarkers
of gut integrity and intestinal inflammation. Logistic linear regression models were
implemented to analyze associations between gut integrity damage, cocaine use and
vitamin D status. Analyses were adjusted for potential confounding factors including age,
gender, CD4+ T count and BMI. Logistic regression models included dependent variable
as high levels of gut integrity damage at the following cut-offs: I-FABP ≤ or ≥ median.
An alpha less than 0.05 was considered significant. All statistical analyses were
performed using SPSS version 23.
Results
Participant Characteristics
A total of 100 PLWH were selected for this study. The proportion of cocaine nonusers was greater (66%, n=66), than that of cocaine users (34%, n=34). For the two
groups, mean age was 53.37±6.88 years old. Cocaine users were older than non-users,
however, this difference was not statistically significant (P=0.338). Most participants
were male (51%), and African American (66%). Participants had a mean duration of
known HIV diagnosis of 17.21±7.28 years. All participants were on ART and had
suppressed viral load (<200 copies/mL) with a median of 48.5 (Interquartile range: 20307) copies/mL Among all participants, 19% used marijuana, 11% used opioids, 1% used
heroin and 2% used fentanyl (data not shown).

125

Cocaine users had higher AUDIT score than non-users (3.12±2.50 vs. 2.03±1.96
respectively, P=0.031), indicating greater alcohol use among cocaine users. Participants
had a mean BMI of 28.70±5.76 kg/m2 which classified most of them as overweight and
37% were obese. In regard to vitamin D status, 50% of participants were considered
deficient (≤20 ng/ml), 32% insufficient (21-29 ng/ml) and 18% sufficient (>30ng/ml).
Most of the samples were collected during winter (47%) and fall (27%) seasons.
Cocaine users had higher levels of I-FABP than non-users (2866.97±798.06 vs.
2337.56±1072.95 respectively, P=0.014) indicating greater gut integrity damage.
Cytokines IL-17 and IL-22 are considered biomarkers for intestinal inflammation; there
were no differences between cocaine users and non-users in regard to intestinal
inflammation. However, for both IL-17 and IL-22, most of the participants exhibited low
levels, which indicates the presence of inflammation in the intestine (IL-17: 89.3% and
IL-22: 86.9%; Table 1). Low levels of these cytokines indicate that IL-17 and IL-22producing cells were affected by ongoing inflammation in the gut, which may continue to
promote disruption of the mucosa immunity and integrity.33–36 In addition, cocaine users
had higher levels of MT than non-users (0.72±0.12 vs. 0.53±0.24 respectively, P<0.001).
Vitamin D levels did not differ between groups (Table 1).
Correlations
A Pearson product-moment correlation was run to determine the linear
relationship between continuous variables. There was a positive correlation between BMI
and CD4 + T cell count (r = 0.201, P =0.046), IL-17 and IL-22 levels (r =0.585,
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P<0.001). There was an inverse correlation between BMI and age (r = -0.231, P =0.021).
Although not statistically significant, there was a trend for inverse correlations between
I-FABP levels and BMI (r = -0.198, P =0.05), IL-17 and CD4+ T cell count (r=-0.211,
P=0.05) and, vitamin D and I-FABP levels (r = -0.198, P=0.05) (Table 2).
Association between Cocaine use and High Levels of Gut Integrity Damage
Logistic regression analyses indicated that cocaine use was significantly
associated with high levels of gut integrity damage (I-FABP ≥ median 2460.43 pg/mL)
(P=0.042) after controlling for age, gender, CD4+ T cell count, vitamin D levels and
participants with intestinal inflammation (IL-22 levels under LOD). The model correctly
classified 59.3% of cases. In addition, cocaine users had 3.04 times higher odds to exhibit
high levels of gut integrity damage than non-users (OR: 3.039 95% CI: 1.039, 8.890;
P=0.042) (Table 3). Analysis were conducted with vitamin D status, for both deficiency
and insufficiency, however, these were not significantly associated with high levels of gut
integrity damage in our participants (data not shown).
Table 4 showed that among cocaine users, 42.9% exhibited high levels of gut
integrity damage [I-FABP ≥ median 2460.43 (IQR: 1813.63-2995.61) pg/mL]. Also,
among individuals who had high levels of MT [LPS levels ≥ median 0.63 (IQR:0.480.73) EU/mL], 59.2% exhibited high levels of gut integrity damage. These findings
indicated that cocaine use posed an important threat for gut integrity contributing with
increased intestinal permeability and high levels of MT. None of the parameters for
vitamin D levels, BMI and HIV disease progression were significantly associated with
high levels of gut integrity damage.
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Association between Cocaine use and Intestinal Inflammation
Intestinal inflammation was assessed by IL-17 and IL-22 levels. Low levels of
these cytokines indicate that IL-17 and IL-22-producing cells were impaired probably
due to HIV enteropathy. Most of our participants exhibited low levels of IL-17 and IL-22
(89.3% and 86.9%, respectively) (Table 1). In participants who exhibited low levels of
IL-22 (<0.01 pg/mL), cocaine use was significantly associated with high levels of gut
integrity damage (I-FABP ≥ median 2460.43 pg/mL) (P=0.037). The model correctly
classified 59.2% of cases. In addition, cocaine users with low levels of IL-22, had 3.42
times higher odds to exhibit high levels of gut integrity damage than cocaine users with
levels of IL-22 >0.01 pg/mL (OR: 3.424 95% CI: 1.076, 10.900; P=0.037) (Table 5). This
association remained significant after adjusting for age, gender, CD4+ T cell count, BMI
and vitamin D levels. Analysis were conducted with vitamin D status, for both deficiency
and insufficiency, however, these were not significantly associated with high levels of gut
integrity damage (data not shown).
Dietary Intake Characteristics in Study Participants
Table 6 describes the dietary intake characteristics of participants. The 2015-2020
USDA Dietary Guideline Recommendations for Americans37 were implemented to
compare total percent of fat from caloric intake (<35% caloric intake), cholesterol (<300
mg/d), fiber (28g/d) and vitamin D intake (600 IU/d). We calculated the proportion of
participants exceeding these recommendations. All participants exceeded
recommendations for cholesterol intake (331.90 ± 317.43 mg/d) but no differences were
observed between cocaine and non-cocaine users (P=0.887). For total percent of calories
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from fat (≥35%) 46% of participants exceeded recommendation, indicating that a pattern
for a high fat diet was reported. All participants had inadequate intake of fiber
(14.66±11.99 gr/d) and vitamin D (18.55±35.18 IU/d) but no differences were observed
between cocaine and non-cocaine users (P=0.458 and P=0.723, respectively).
Interestingly, a great proportion of participants did not consume vitamin D as reported in
the 24-hour recall.
Associations between Gut Integrity Damage and Dietary Fat Intake
Logistic regression analyses indicated that a high fat diet (total fat ≥35% calories)
was significantly associated with high levels of gut integrity damage [I-FABP ≥ median
2460.43 (IQR:1813.63-2995.61) pg/mL] after controlling for age, gender, total fat intake
and obesity. The model correctly classified 58.2% of cases. In addition, participants who
followed a high fat diet (total fat ≥35% calories) had 3.38 times higher odds to exhibit
high levels of gut integrity damage than those who did not follow a high fat diet (OR:
3.38 95% CI: 1.256, 9.123; P=0.016) (Table 7).
Discussion
We examined associations between gut integrity, intestinal inflammation and
vitamin D status in the context of cocaine abuse among PLWH. Our data suggested that
our participants showed similar I-FABP levels to the ones reported in others studies
conducted in PLWH, indicating great damage to the gut integrity.27,30,38 Cocaine users
had higher levels of I-FABP than non-users, showing greater gut integrity damage in
cocaine users. However, this effect was not seen for markers of intestinal inflammation
(IL-17 and IL-22) and vitamin D levels.
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We also showed that cocaine was a significant predictor for high I-FABP levels
even after controlling for age, gender, CD4+ T cell count and vitamin D levels. To the
best of our knowledge, this is the first study showing an association between cocaine use
and gut integrity damage among PLWH. It is important to mention that all our
participants were on stable ART, suppressed viral load (<200 copies/mL) and did not
report hazardous drinking (AUDIT score >8), which implies that cocaine is a key player
for destabilizing gut integrity in PLWH. Studies have reported that cocaine has the ability
to dysregulate the expression of the tight junction proteins in the intestinal epithelium,
promoting gut integrity damage, hyperpermeability, intestinal inflammation and
disruption of the microbiome.39–41 Our findings suggest that in addition to deleterious
effects of HIV on the GI tract, cocaine seems to be an important factor that aggravates the
ongoing inflammation and damage to the gut integrity in HIV infection.
A unique finding from this study was that cocaine users were 3.04 times more
likely to have high damage to the gut integrity (I-FABP ≥ median 2460.43 pg/mL) than
non-users. This may indicate the harmful influence of cocaine in the GI mucosa that
promotes destruction of tight junctions, creating a “leaky” gut that allows the passage of
microbial products into systemic circulation.
Participants with high damage to the gut integrity (I-FABP ≥ median of 2460.43
pg/mL) also had high levels of MT (LPS ≥ median of 0.63 EU/mL) supporting previous
findings on the role of HIV and SIV on the damage to the gut integrity and MT in
humans and rhesus macaques.24 During HIV infection, there is a massive loss of CD4+ T
cells in the GI lamina propia. This loss also affects a subtype of CD4+ T helper 17 cells
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(Th17) in the intestine, which are responsible for the intestinal homeostasis, mucosal
regeneration and integrity 42,43 creating an environment for gut integrity damage,
increased intestinal permeability and MT.
In regard to vitamin D status, half of our participants were vitamin D deficient
and one third were insufficient. These rates are comparable to the ones reported by other
cohort studies showing a high incidence of vitamin D deficiency in PLWH in the US.44,45
Our cohort is mostly comprised of African Americans and Hispanics and almost half of
the cohort was overweight ,which is a risk for vitamin D deficiency.18 However, vitamin
D status, deficiency or insufficiency, was not associated with high levels of gut integrity
damage (I-FABP ≥ median 2460.43 pg/mL) in our participants. This finding suggests that
cocaine use is an important and significant factor for high levels of gut integrity damage
in our cohort.
Additionally, we showed that cocaine use was significantly associated with higher
levels of gut integrity damage in participants who exhibited intestinal inflammation (low
levels of IL-22), and that these individuals were 3.43 times more likely to exhibit high
gut integrity damage than individuals who did not have intestinal inflammation. Several
lines of evidence have suggested that intestinal CD4+ T cells that produce IL-17 and IL22 are severely compromised during HIV infection, provoking intestinal inflammation,
MT, immune activation and ultimately disease progression.24,46–49 In our study, we
showed that most of our participants exhibited intestinal inflammation supporting the
idea that the depletion of CD4+ T cell decreases IL-17 and IL-22 production. Most
importantly, this is the first study suggesting that cocaine use worsen the increased gut
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integrity damage during intestinal inflammation among PLWH. This findings contribute
to the existing evidence that supports targeting drug abuse,50 Th17 producing cells and
gut microbiome as potential areas for reducing HIV reservoir in the intestine, and for
HIV remission and future potential cure.51,52 Our data do not support that impairment of
vitamin D status (deficiency or insufficiency) may be a significant factor for high levels
of gut integrity damage in our participants.
Our dietary data showed that PLWH in Miami seemed to follow a dietary pattern
characterized by a high fat, high cholesterol diet. These findings support previous studies
showing that PLWH had an increase of total fat, saturated fat and cholesterol and low
fiber intake53–56 posing a risk for the developments of chronic conditions, including
cardiovascular disease, obesity and inflammation. Our participants had inadequate
vitamin D intake and a great proportion of them did not consume vitamin D at all. This
study suggests that personalized dietary interventions that focus on healthy eating and
physical activity may be beneficial in the management of HIV.
Individuals who followed a high fat diet seemed to have higher levels of gut
integrity damage. Our study is among the first to show associations between diet and
damage to the gut integrity in PLWH. In another study, researchers did not find
associations between high fat diet and damage to the gut integrity.56 Differences may be
due to methodological approaches, including dietary intake assessment and sociodemographics characteristics of study participants. Nevertheless, a growing body of
evidence comprised of animal and human studies have shown the effects of high fat diet
on gut integrity.57 In this regard, a study conducted in obese mice found that a high fat
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diet seemed to disrupt gut integrity promoting increased permeability58 via the activation
of mast cells in the intestinal mucosa. These cells are responsible for the release of proinflammatory cytokines in the intestine59, including TNF-a, which promotes destruction
of tight junction structures leading to gut integrity damage and increased permeability.60
Another study conducted in mice fed with a high fat diet suggested that the expression of
tight junction proteins (claudin-1, claudin-3 and occluding) were reduced and gut
microbiome was affected, posing ideal conditions for intestinal permeability and
inflammation.61,62
Our study has limitations. The cross-sectional design does not allow us to
establish causation. Intestinal inflammation markers (IL-17 and IL22) were available
only for 85 study participants. Dietary intake data were assessed by one 24-hour recall.
The analysis of a 24-hour food recall is limited by important factors such as the
interviewee’s memory, concepts of food portion size, and current versus historical food
consumption. The results of this study need to be interpreted with caution due to the
specific conditions surrounding the study such as socioeconomics, ethnic distribution and
geography, as this study included only people on stable ART and controlled viral load.
This study, however, provides important clinical evidence that supports the development
of strategies to ameliorate and prevent cocaine abuse and vitamin D deficiency among
PLWH.
Conclusion
Our data demonstrated that cocaine abuse and a high fat diet are independently associated
with high levels of gut integrity damage and intestinal inflammation in PLWH despite
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ART use and viral suppression. Our study provided preliminary data for the development
of future research focusing on dietary interventions for gut health and counseling on drug
to more effectively decrease intestinal damage, and ultimately chronic inflammation
among PLWH.
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Table 1. Participants Characteristics
Characteristics

Total
(n=100)

Cocaine Nonusers (n=66)

Cocaine Users
(n=34)

P value

53.37±6.88

52.89±7.38

54.29±5.77

0.338

Gender (male)

51(51)

35 (35)

16 (16)

0.361

Race/Ethnicity
African American
Hispanic
White
Other

66 (66)
29 (29)
28 (28)
6 (6)

38 (38)
23 (23)
24 (24)
4 (4)

28 (28)
6 (6)
4 (4)
2 (2)

0.011
0.103
0.100
0.603

CD4+ T (cells/μL)

630.08±344.07

628.80±298.12

632.64±426.63

0.963

HIV Viral Load (copies/mL)

48.50 (20-307)

59 (31.5-140.25)

40 (26.5-136)

0.497

17.21±7.28

18.01±7.23

15.64±7.14

0.150

AUDIT score

2.4±2.19

2.03±1.96

3.12±2.50

0.031

Smoking (yes)

47 (47)

24 (24)

23 (23)

0.300

28.70±5.76

28.89±5.82

28.33±5.71

0.648

37 (37)

24 (24)

13 (13)

0.511

2515.83± 1072.95

2337.56±1072.95

2866.97±798.06

0.014

IL-17 pg/mL

4.01±7.94

6.12±15.77

1.92±0.11

0.084

IL-22 pg/mL

0.11±0.32

0.11±0.43

0.09±0.218

0.813

Participants with low levels IL17 pg/mL*

89.3 (75)

86.2 (50)

96.2 (25)

0.164

Participants with low levels IL22 pg/mL*

86.9 (73)

87.9 (51)

84.6 (22)

0.460

LPS (EU/mL)

0.59±0.23

0.53±0.24

0.72±0.12

<0.001

20.97 (16.9627.84)

19.80 (16.6826.60)

23.07 (19.2329.59)

0.087

Vitamin D Status
Deficient ≤20 ng/mL
Insufficient 21-29 ng/mL
Sufficient ³30 ng/mL

50 (50)
32 (32)
18 (18)

35 (35)
21 (21)
10 (10)

15 (15)
11 (11)
8 (8)

0.527
1.000
0.411

Seasonality
Winter
Fall
Spring
Summer

43 (43)
27 (27)
22 (22)
8 (8)

30 (30)
18 (18)
14 (14)
4 (4)

13 (13)
9 (9)
8 (8)
4 (4)

0.529
1.000
0.803
0.439

Age, years

Duration of known HIV (years)

BMI (kg/m2)
Obesity (BMI>30kg/m2)
I-FABP pg/mL

Vitamin D ng/mL

Bold indicates statistical significance at P<0.05. Data for continuous variables are summarized as mean ± standard deviation and
median (interquartile range IQR) with statistical comparison using T test and Mann-Whitney, respectively. Categorical variables are
summarized as count n (%) to test for proportions using Chi square. BMI: body mass index; I-FABP: Intestinal Fatty Acid Binding
Protein; IL-17: interleukin 17; IL-22: interleukin 22; LPS: Lipopolysaccharide. *Indicates proportion of participants with low levels of
IL-17 and IL-22.
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Table 2. Pearson Correlation Coefficients
Variable
Age
CD4+
AUDIT
Age
1
CD4+
-.09
1
AUDIT
-.06
-.15
1
BMI
-.23*
.20*
.13
I-FABP
.07
-.01
.08
LPS
-.06
.06
.04
IL-17
.08
-.21**
.03
IL-22
.13
-.17
.17
Vit. D
.13
.02
.07

BMI

I-FABP

LPS

IL-17

IL-22

Vit. D

1
-.17**
-.17
-.07
-.07
.04

1
.14
-.09
-.03
-.19**

1
.06
-.13
-.05

1
.58*
-.02

1
.05

1

*Correlation is significant at the 0.05 level (2-tailed).
**Correlation showing a trend P=0.05.

Table 3. Logistic Regression Analyses Predicting The Likelihood of High Levels of Gut Integrity Damage
(I-FABP ≥ Median 2460.43 pg/mL) in Study Participants
Variable
β
SE
OR
95% CI OR
P-value
Age
0.044
0.034 1.045 0.978, 1.116
0.197
Gender
-0.259
0.529 0.772 0.274, 2.177
0.625
Log transformed CD4+ T cell count (cells/μL)
0.310
0.571 1.363 0.445, 4.174
0.588
Cocaine (yes)
1.111
0.548 3.038 1.038, 8.894
0.043
Vitamin D levels (ng/mL)
-0.035
0.032 0.966 0.907, 1.028
0.277
Participants with low levels IL-22 (pg/mL) *
1.063
0.774 2.896 0.635, 13.198 0.169
Bold indicates statistical significance at P<0.05
*Participants who exhibit IL-22 levels under Limit of Detection (LOD)

Table 4. Differences Between Median Groups of I-FABP and Cocaine Use, Microbial Translocation and
Vitamin D Levels
Variable
I-FABP (≤ 2460.43 pg/ml) I-FABP (≥ 2460.43 pg/ml) P-value
Cocaine use (yes) (%)
25.5
42.9
0.049
CD4+ T cell count (cells/μL)
642.6 ± 390.99
616.77 ± 289.584
0.708
HIV viral load (copies/mL)
98.78 ± 75.12
70.77 ± 80.23
0.414
BMI (kg/m2)
29.42 ± 5.58
27.95 ± 5.89
0.204
IL-17 (pg/mL)
5.79 ± 14.32
3.84 ± 12.1
0.503
IL-22 (pg/mL)
0.12 ± 0.34
0.09 ± 0.41
0.738
LPS (≥0.63 EU/mL) (yes) (%) *
40.8
59.2
<0.001
Vitamin D (ng/mL)
23.72 ± 8.55
22.87 ± 7.62
0.603
Bold indicates statistically significant at P<0.05
*LPS above the median (>0.63 EU/ml)
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Table 5. Logistic Regression Analyses Predicting The Likelihood of High Levels of Gut Integrity Damage
(I-FABP ≥ 2460.43 pg/mL) in Participants with Intestinal Inflammation (Il-22 <0.01 pg/mL)
Variable
β
SE
OR
95% CI OR
P-value
Age
0.027
0.035 1.028
0.959, 1.101
0.443
Gender
0.087
0.591 1.091
0.343, 3.473
0.883
Log transformed CD4+ T cell count (cells/μL) 0.514
0.611 1.671
0.504, 5.541
0.401
Cocaine (yes)
1.233
0.591 3.430
1.077, 10.934 0.037
Vitamin D (ng/mL)
-0.008
0.036 0.992
0.926, 1.064
0.831
BMI (kg/m2)
-0.041
0.045 0.960
0.879, 1.049
0.370
Bold indicates statistical significance at P<0.05

Table 6. Dietary Intake Characteristics
Nutrient
Calories (cal)
Protein (gr)
Carbohydrate
(gr)
Total Fat (gr)
Total Fat
intake >35%**
Cholesterol
(mg)
Dietary Fiber
(gr)
Vitamin D
(IU)
Inadequate
Vitamin D
intake***

Recommended
Range*
1800-2200
46-56
130

Total (n=100)

Cocaine users
(n=34)
1937.84±1329.9
80.39±53.15
230.06±166.90

P-value

1991.20±1233.32
88.42±96.45
242.57±172.35

Cocaine nonusers (n=66)
2017.87±1191.7
92.43±112.18
248.83±175.93

20-35

75.90±51.07
46

74.80±46.12
60.9

78.12±60.48
39.1

0.783
0.142

300

341.90±317.43

338.93±343.11

347.84±263.46

0.887

25.2-30.8

14.66±11.99

15.03±11.96

13.394±12.12

0.458

600

18.55±35.18

19.42±36.28

16.81±33.32

0.723

-

67 (67)

66.7 (44)

69.7 (23)

0.473

0.763
0.470
0.612

* Recommended ranges based on adults who consume 1800-2200 kcals daily. Variations exits by age, sex and activity level.
**Participants with high fat diet (>35% Calories from Total Fat Intake)
***Participants with inadequate Vitamin D intake (0 IU/day)

Table 7. Logistic Regression Analysis of Dietary Factors Predicting High Gut Integrity Damage Levels in
Study Participants
Variable
β
SE
OR
95% CI OR
P-value
Age
0.014
0.032
1.014
0.952, 1.081
0.657
Gender
-0.056
0.440
0.946
0.399, 2.241
0.899
Participants with high fat diet*
1.220
0.506
3.386
1.256, 9.123
0.016
Total fat (gr)
-0.009
0.005
0.991
0.981, 1.001
0.085
Obesity
-0.619
1.846
0.539
0.206, 1.405
0.206
Bold indicates statistically significant at P<0.05
*Participants with high fat diet (>35% Total Fat Intake)
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CHAPTER VI: SUMMARY OF CONCLUSION AND IMPACT ON PRACTICE

This study investigated the association of gut integrity, microbial translocation
(MT), immune activation, inflammation and vitamin D status in the context of cocaine
abuse among People Living with HIV (PLWH).
It has been well stablished that HIV destroys the intestinal CD4+ T cells causing a
major disruption in the intestinal immune system characterized by local inflammation and
destruction of the gut integrity. These events create an environment where the ability of
the intestine to protect its integrity is compromised, generating a “leaky gut” that allows
the passage of microbial products into systemic circulation, a process called microbial
translocation (MT). The presence of MT products in the systemic circulation activates the
immune system and contributes to the ongoing inflammation caused by HIV despite
Antiretroviral Therapy (ART) and viral suppression.1–9
Illicit drug abuse, particularly cocaine, is prevalent among PLWH.10 Cocaine
poses harmful effects to the immune system, gut microbiome, and promotes HIV disease
progression and mortality among PLWH.11–14 However, the impact of cocaine use on gut
integrity, MT, immune activation and inflammation has not been fully investigated. Only
one study has shown disruption of the microbiome but no association with MT.14
To the best of our knowledge, our study is the first to demonstrate the impact of
cocaine use on MT, immune activation, inflammation and gut integrity among PLWH.
Our data revealed that cocaine users had higher levels of MT than non-users, and that
cocaine use was a significant predictor for markers of MT (LPS) and immune activation
(sCD163 and sCD27). We showed that cocaine users were 6.66 times more likely to
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exhibit high MT levels than non-users, which were associated with intestinal
inflammation and ultimately high levels of MT. These findings suggest the damaging
effect of cocaine in the Gastrointestinal (GI) mucosa.
Although all our participants were on stable ART and virally suppressed, we
found that lower CD4+ T cells were associated with MT levels, which support the
premise of the continuous destructive effects of HIV on the GI immune system and poor
reconstitution of CD4+T cells despite of ART use.8,9,15–17
Our analyses suggested that MT was a significant predictor of systemic
inflammation in our participants, an association that had been established previously in
other studies in PLWH on ART and viral supression.18–20 It has been recognized that
damage to the gut integrity during HIV infection is a major driver for MT, immune
activation and chronic inflammation.6,21–25 Although, cocaine use was not directly
associated with inflammation in our study, we showed that cocaine users had higher MT
levels than non-users; this could indicate the possible role of cocaine in the gut integrity,
promotion of MT, and ultimately systemic inflammation.26,27
This study also revealed that among cocaine users living with HIV, alcohol use
was associated with inflammation. This finding agrees with previous evidence showing
an association of alcohol and cocaine with inflammation among PLWH.28 Alcohol and
cocaine are often used together,29 and this combination produces a synergistic effect that
increases the time and severity of immune and neurological toxicity, as well as the effects
on dependence.30
Additionally, our findings indicated that an increase on BMI independently
predicted inflammation in cocaine users living with HIV. This is a novel finding that
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suggests that cocaine and weight gain provide a cooperative effect that not only promotes
systemic inflammation and HIV disease progression, but it may increase the risk for nonAIDS related conditions, such as cardiovascular disease.
Our data suggested that cocaine users living with HIV also had higher I-FABP
levels than non-users, which indicated greater damage of the gut integrity in this
population. Cocaine was an independent predictor of high levels of gut integrity damage,
and cocaine users were 3.04 times more likely to exhibit high levels of gut integrity
damage than non-users. Evidence has shown that cocaine has the ability to dysregulate
the expression of the tight junction proteins in the intestine, promoting the damage of the
gut integrity, increased permeability, intestinal inflammation and disruption of the
microbiome.26,27,31 Our findings suggest that in addition to the deleterious effects of HIV
on the GI tract, cocaine use seems to be an important factor in exacerbating the ongoing
inflammation and in damaging gut integrity in HIV infection.
It is noteworthy that many of our participants had intestinal inflammation as
measured by low levels of cytokines IL-17 and IL-22. Several studies have suggested
that intestinal CD4+T cells that produce IL-17 and IL-22 are severely compromised
during HIV infection, provoking intestinal inflammation, MT, immune activation and
ultimately disease progression.32–36
In those participants who had intestinal inflammation, cocaine use was a
significant predictor for high levels of gut integrity damage. To the best of our
knowledge, this is the first study showing an association between cocaine use and
damage of the gut integrity during intestinal inflammation among PLWH. This finding
supports the importance of targeting drug abuse,37 intestinal inflammation and gut
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microbiome as prospective targets for reducing HIV reservoir in the intestine, and
achieving remission and cure.38,39
In regard to vitamin D status, we found that half of our participants were deficient
and one third were insufficient. These prevalence rates are comparable to the ones shown
by other studies demonstrating a high prevalence of vitamin D deficiency among PLWH
in the US.40,41 Our cohort is comprised of African Americans and Hispanics and almost
half of the cohort was overweight, all of which represent risk factors for vitamin D
deficiency.42
In those participants who were vitamin D deficient and insufficient, those who
used cocaine had higher MT levels than non-users. Importantly, cocaine use was
associated with MT levels in both vitamin D deficient and insufficient participants,
indicating that cocaine is a significant driver for MT when vitamin D status is impaired.
This effect, however, was not observed for immune activation, inflammation and gut
integrity damage.
The results of our study suggested that cocaine is an independent factor that
aggravates gut integrity and intestinal inflammation and drives MT and immune
activation among PLWH. Cocaine is one of the most addictive illicit drugs. In this regard,
a very interesting study conducted in mice exposed to cocaine, demonstrated that
disruption of the microbiome may influence behavioral responses, particularly the
rewarding and sensitizing properties of cocaine via the gut-brain axis.31
To the best of our knowledge, there is only one study conducted in humans that
reported that individuals who use cocaine exhibit depletion of the gut microbiome.14
These important pieces of evidence suggest the possibility for the GI tract, particularly
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gut microbiome, to be an important target for the prevention or treatment of drug
addiction.
Studies have demonstrated that cocaine users living with HIV do not follow an
optimal diet, and have higher incidence of food insecurity and alcohol consumption than
cocaine non-users.14,43,44 Our dietary data showed that cocaine users living with HIV
exceeded dietary recommendations for total % of calories from fat and cholesterol, and
had poor fiber intake. These are considered key nutrients for both disruption and
maintenance of gut integrity and microbiome.45–48
Therefore, there is an imperative need to tailor programs that focus on effective
counseling on drug abuse and lifestyle modification. Nutrition interventions focused on
gut health may help to prevent and ameliorate gut integrity damage, disruption of gut
microbiome and associated inflammation in a vulnerable population such as cocaine
users living with HIV. Further research is needed to continue examining the association
of drug abuse and intestinal health as a key area to overcome some of the many
challenges for HIV management, which are to reduce chronic inflammation and HIV
disease progression, in order to achieve better control of the condition.
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CHAPTER VII: FUTURE RESEARCH

The results from this study suggested that cocaine use was a major driver for
disruption of gut integrity, microbial translocation, immune activation and inflammation
among People Living with HIV (PLWH). Thus, the association among cocaine use, gut
integrity, microbial translocation, immune activation and inflammation in a longitudinal
study with a larger sample size may provide a better understanding of the impact of
substance abuse on HIV disease progression. More studies are needed to elucidate the
mechanisms behind the harmful effects of cocaine on microbial translocation and
intestinal inflammation among PLWH, and for identifying potential targets for treatment.
In addition, further clinical trials focused on gut health, gut microbiome restoration and
cocaine abuse are warranted to provide clinically meaningful data that can be translated
into future recommendations for HIV management and behavioral and clinical
interventions.
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